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ABSTRACT 
 
 
Aortic valve stenosis (AVS) is the most common valvular disease in Western countries. 
Pharmacological prevention of AVS having proved unsuccessful, its current treatment 
is still valve replacement. The etiology of AVS is multifactorial, both genetic and 
external risk factors predisposing to the active pathological process eventually leading 
to clinically manifest stenosis. Histological features of the disease resemble those of 
atherosclerosis, including the accumulation and modification of lipoproteins, 
inflammation, extracellular matrix remodeling, and calcification. Furthermore, valvular 
interstitial cells undergo phenotypic differentiation into actively proliferating 
myofibroblasts, which contribute to the local inflammatory response as well as 
extracellular matrix remodeling in stenotic aortic valves. Blood vessels also grow into 
the normally avascular valve leaflets already in the early stages of the disease. 
 
This thesis aimed at elucidating the mechanisms behind the pathological 
neovascularization of the stenotic aortic valves. Furthermore, we characterized 
valvular lymphangiogenesis and investigated potential factors contributing to the 
balance between valvular angiogenesis and lymphangiogenesis, focusing on the role of 
valvular myofibroblasts and mast cells. For this purpose, we studied a total of 117 
stenotic valves obtained at valve replacement surgery, and 49 control valves obtained 
at cardiac transplantations, at valve replacement surgery due to aortic valve 
regurgitation, or from deceased organ donors whose hearts were unsuitable for use as 
grafts. The valve leaflets were either used freshly for myofibroblast cell culture or 
frozen for e.g. PCR and immunohistochemical analyses. 
 
First, we assessed the adverse extracellular matrix remodeling of stenotic aortic 
valves, a process necessary for angiogenic sprouting to occur. We found that the 
mRNA expression levels of cathepsins S, K, and V, and their inhibitor cystatin C were 
higher in stenotic aortic valves than in control valves. Furthermore, the total activity of 
such cathepsins was increased in AVS. In immunohistochemical stainings, the 
expressions of cathepsin S, cathepsin V, and cystatin C localized to valvular 
macrophages, chondroblast-like cells, and endothelial cells lining both the valvular 
surface and the neovessels in the stenotic valves.  
 
Next, we characterized the neovessels and lymphatic vessels in stenotic aortic valves 
and control valves using immunohistochemistry. We found that in addition to 
immature microvessels, the stenotic aortic valves contained organized arterioles, 
indicating an advanced stage of angiogenesis. Lymphatic vessels correlated with 
valvular blood vessels, but were present in much fewer numbers. Valvular mast cells 
resided close to neovessels and secreted the angiogenic Vascular endothelial growth 
factor A (VEGF-A). Furthermore, we showed that the lymphangiogenic growth factors 
VEGF-C and VEGF-D are locally produced in the aortic valves, and that the receptors 
10 
 
for all these VEGFs, VEGFR-2 and VEGFR-3, are upregulated in AVS. We also identified 
several factors that induce VEGF-A secretion in cultured valvular myofibroblasts. These 
include mast cell-derived components, the inflammatory cytokine TNF-α, hypoxia, and 
cigarette smoke. Myofibroblasts were also able to promote VEGF-A secretion by 
cultured human mast cells, suggesting potential angiogenic interplay between these 
two valvular cell types. Interestingly, mast cell-derived proteases also efficiently 
degraded the lymphangiogenic growth factor VEGF-C. Thus, by secreting VEGF-A, by 
urging myofibroblasts to produce VEGF-A, and by releasing VEGF-C-degrading 
proteases, mast cells may strongly influence the observed imbalance between valvular 
blood vessels and lymphatic vessels. 
 
Finally, we investigated the potential effects of oxidized low-density lipoprotein 
(oxLDL) on valvular angiogenesis. We found that oxLDL induces the expression of 
several inflammatory cytokines in cultured myofibroblasts. Moreover, we identified 
oxLDL-binding scavenger receptors to be locally expressed in the aortic valves. The 
mRNA expression levels of scavenger receptor class A type 1 (SR-A1) and Lectin-like 
oxidized LDL receptor-1 (LOX-1) were increased in AVS, whereas CD36 was 
downregulated in stenotic valves. Furthermore, the expression of LOX-1 in cultured 
valvular myofibroblasts increased in response to mast cell-derived components and 
TNF-α. The observed changes in valvular scavenger receptor expression particularly 
favor inflammation and angiogenesis. 
 
In conclusion, several angiogenic factors were found to be activated in stenotic aortic 
valves. Furthermore, valvular mast cells and myofibroblasts were identified as 
potential players promoting valvular angiogenesis and contributing to the pathological 
imbalance between valvular angiogenesis and lymphangiogenesis. This imbalance, in 
turn, could facilitate the harmful infiltration of inflammatory cells and lipoproteins into 
the stenotic aortic valves and ultimately contribute to the progression of the disease. 
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TIIVISTELMÄ 
 
 
Aorttaläpän ahtauma on väestön ikääntymisen myötä yleistynyt sairaus, johon ei ole 
lääkehoitoa. Aorttaläpän ahtautuminen johtaa sydämen vasemman kammion 
painekuormitukseen ja lopulta vajaatoimintaan, ja jo taudin lievään muotoon liittyy 
kohonnut sydänperäisen äkkikuoleman riski. Tauti havaitaan yleensä myöhään, sillä se 
on pitkään oireeton. Oireiden ilmaantuminen onkin aihe keinoläppätoimenpiteelle. 
Taudin riskitekijöitä ovat korkean iän lisäksi miessukupuoli, korkea verenpaine, 
tupakointi, diabetes ja veren suuri LDL-kolesterolin pitoisuus. Vaikka riskitekijät ovat 
osittain samat kuin sepelvaltimotaudissa, vain noin puolella läppäpotilaista on 
merkittävä sepelvaltimotauti.  
 
Kudostasolla läpän ahtautumiseen johtaa aktiivinen tapahtumaketju, jonka katsotaan 
alkavan läpän pintaa verhoavan endoteelisolukerroksen vaurioitumisesta. Sitä seuraa 
tulehdussolujen, kuten syöttösolujen, ja kolesterolin kertyminen läpän rakenteisiin. 
Lisäksi läpän sidekudossolut aktivoituvat sidekudostumista edistävään suuntaan 
myofibroblasteiksi ja läpissä tuotetaan runsaasti sidekudosta hajottavia proteaaseja. 
Normaalisti suonettomiin aorttaläppäliuskoihin kasvaa taudin myötä uudissuonia, 
jotka voivat edistää tautia kuljettamalla läppiin lisää tulehdussoluja ja rasvoja. Lisäksi 
verisuonien kuljettamat ravinteet ja happi mahdollistavat tulehdussolujen ja 
sidekudossolujen haitallisen toiminnan. Imusuonet puolestaan voisivat toimia 
verisuonien vastavaikuttajina kuljettamalla tulehdussoluja ja rasvoja kudoksista pois. 
Ahtautuneiden aorttaläppien uudissuonittumisen ja imusuonikasvun taustalla olevat 
mekanismit ovat kuitenkin tähän asti olleet pitkälti tuntemattomia. 
 
Tämän väitöskirjan osatyöt tähtäsivät ahtautuneiden aorttaläppien 
uudissuonittumisen luonnehdintaan sekä uudissuoni- ja imusuonikasvun taustalla 
olevien tekijöiden kartoittamiseen. Osatöissä on tutkittu 117 aorttaläpän ahtauman 
vuoksi leikatun potilaan aorttaläppää. 49 kontrolliläppää kerättiin aorttavuodon vuoksi 
leikatuilta potilailta, sydämensiirroissa poistetuista sydämistä ja käyttämättä jääneistä 
sydänsiirteistä.  
 
Ensimmäinen osatyö käsitteli katepsiineja S, K, ja V, sekä niiden estäjää kystatiini C:tä. 
Nämä proteaasit osallistuvat sidekudoshajotukseen, joka on välttämätöntä uusien 
verisuonien versoamiselle. Toisessa ja kolmannessa osatyössä selvitimme 
uudissuonten ja imusuonten määrää ja laatua ahtautuneissa ja terveissä aorttaläpissä 
sekä niiden yhteyksiä läpän kalkkiutumiseen ja tulehdusasteeseen. Lisäksi eristimme 
ihmisen aorttaläpistä myofibroblasteja ja tutkimme niiden vastetta erilaisiin 
ärsykkeisiin, kuten tulehdusvälittäjäaineisiin, hapenpuutteeseen ja tupakansavuun. 
Lisäksi tutkimme myofibroblastien ja syöttösolujen vaikutuksia toisiinsa 
soluviljelymallissa ja osoitimme, että niiden välisellä vuorovaikutuksella voi olla 
uudissuonittumista edistäviä vaikutuksia. Neljännessä osatyössä selvitimme aiemmin 
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ahtautuneista läpistä löydettyjen hapettuneiden LDL-hiukkasten vaikutuksia 
uudissuonittumiseen. Havaitsimme, että näiden hiukkasten vaikutuksia välittävien 
jätereseptorien ilmentyminen on ahtautuneissa aorttaläpissä muuttunut tulehdusta ja 
uudissuonittumista edistävään suuntaan. 
 
Tässä väitöskirjassa on kuvattu useita ahtautuneiden aorttaläppien 
uudissuonittumisen mekanismeja. Havaitsimme, että uudissuonten ja imusuonten 
välinen tasapaino on ahtautuneissa aorttaläpissä häiriintynyt suosien mm. 
tulehdussolujen kertymistä läpän rakenteisiin. Näin ollen tämän epätasapainon 
taustatekijät, kuten läpän syöttösolujen ja myofibroblastien vuorovaikutukset, voivat 
myös edistää aorttaläpän ahtauman etenemistä. 
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I INTRODUCTION 
 
 
Calcific aortic valve disease (CAVD) and its end-stage, aortic valve stenosis (AVS), have become 
the most common valvular heart diseases in Western countries due to the ageing of the 
population. In younger adults, AVS usually develops when the valve only has two leaflets 
instead of three, which occurs in 1-2 % of the population (Lindroos et al. 1993). Other risk 
factors resemble those of atherosclerosis, but only half of AVS patients manifest significant 
coronary artery disease (Otto et al. 1997), suggesting the existence of distinct pathobiological 
mechanisms.  
 
Histological changes of AVS develop over a long period of time and ultimately lead to 
thickening of the valve leaflets and symptomatic ventricular outflow obstruction. Because the 
symptoms appear late in the course of the disease, the diagnosis is commonly delayed, and the 
prognosis of a symptomatic patient without operation is extremely poor. Indeed, the onset of 
symptoms indicates the need for valve replacement surgery. Since the patients are often 
elderly and have several comorbidities, a pharmacological treatment option would be called 
for. The search for such pharmacotherapeutic targets has, however, been unsuccessful. 
 
Active atheroinflammatory processes have been discovered in stenotic aortic valves. Early 
changes of the disease include endothelial damage, lipid accumulation, infiltration of 
inflammatory cells, neovascularization, fibrosis, and calcium deposition in the affected valve 
leaflets (Olsson et al. 1994a, Otto et al. 1994). Over time, these changes become more 
manifest, and lead to the pathological thickening and stiffening of the valve. Even active bone 
formation and remodeling occur in the normally translucid valves (Mohler et al. 2001, O'Brien 
et al. 1995). Angiogenic processes leading to valvular neovascularization could enable a 
number of the aforementioned pathological processes. More specifically, valvular blood vessels 
could e.g. facilitate the entry of lipids and inflammatory cells into the tissue, and provide 
nutrients and oxygen to the proliferating fibrotic cells in the deeper parts of the valves. 
Although angiogenesis is recognized as a prominent pathological feature in AVS (Soini et al. 
2003), its underlying mechanisms in the aortic valve have remained unknown for the most 
part. 
 
The present thesis aimed at characterizing valvular neovascularization and at identifying some 
of the mechanisms behind the different stages of valvular angiogenesis. First, we studied the 
extracellular matrix remodeling initially required for vascular sprouting. We then investigated 
the valvular production of angiogenic and previously unreported lymphangiogenic growth 
factors as well as their receptors. Finally, we assessed the possible contribution of oxidized low-
density lipoprotein to valvular angiogenesis. We focused on the role of valvular myofibroblasts 
and mast cells, and their interactions in these pathological processes. 
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II LITERATURE REVIEW 
 
 
 Anatomy of the aortic valve 1.
 
The aortic valve opens during ventricular systole, when blood flows from the left ventricle into 
the aorta. The valve closes during ventricular diastole, preventing blood from flowing back into 
the heart from the aorta. The opening surface area is normally 3-4 cm
2
, which can be measured 
by echocardiography. A normal aortic valve is tricuspid, i.e. it consists of three thin leaflets 
(Figure 1A).  Each leaflet consists of strong elastic tissue covered by vascular endothelium. 
Normal valvular structure can be histologically divided into three layers: ventricularis, 
spongiosa, and fibrosa (Figure 1B). The ventricularis, located on the ventricular side of the 
leaflet, mostly consists of elastic fibers. Spongiosa is a loose layer of proteoglycan-rich 
connective tissue and valvular interstitial cells, whereas fibrosa forms a strong collagenous 
structure on the aortic side of the leaflet. In aortic valve stenosis, all these components are 
disrupted leading to a thick, calcified, non-elastic valve structure obstructing blood flow from 
the heart to systemic circulation (Mönckeberg 1904). Due to its central location in the 
circulatory system, the aortic valve is exposed to substantial biomechanical forces for several 
decades. Especially the turbulent blood flow on the aortic side of the valve may increase local 
shear stress, thus triggering endothelial dysfunction and other potentially AVS-initiating 
processes. When examined macroscopically, the calcific deposits of the diseased leaflets 
consistently localize to the aortic side of the valve.  
 
 
 
Figure 1. A) A normal aortic valve viewed from the aortic side. B) The three layers of an aortic 
valve leaflet. Elastic van Gieson stain showing collagen fibers in pink and elastin in dark purple. 
 
 
 
 Clinical course of aortic valve stenosis 2.
 
2.1. Epidemiology 
 
Aortic valve stenosis (AVS) is the end-stage in a wide disease spectrum of calcific aortic valve 
disease (CAVD), characterized by prominent calcification and ventricular outflow obstruction 
(Rajamannan et al. 2011). Earlier stages are generally referred to as aortic sclerosis, the 
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pathological leaflet thickening prior to obstruction. The prevalence of CAVD increases with age. 
In Finland, 60 % of the people past 80 years of age have aortic sclerosis, and 4 % of them 
already manifest clinically significant stenosis (Lindroos et al. 1993). A recent Norwegian 
population-based cohort study on clinically significant AVS reported prevalences of 3.9 % in the 
70-79 year cohort and 9.8 % in the 80-89 year cohort (Eveborn et al. 2013). Rheumatic fever no 
longer significantly contributes to valvular disease due to modern medical practices. The most 
distinct predisposing factor of AVS is a congenitally bicuspid valve, which occurs in 1-2 % of the 
population (Lindroos et al. 1993), but in up to 49% of AVS patients (Roberts and Ko 2005), 
varying between studies. The two-leaflet structure of the bicuspid valve has lower tolerance to 
shear stress, and stenosis usually develops at a younger age (Beppu et al. 1993). However, 
histopathological features seem to be similar in the both types of stenotic valves (Wallby et al. 
2002).  
 
In addition to age and valve structure, several epidemiological risk factors have been 
connected with AVS. These include male gender, hypertension, smoking, elevated levels of 
serum low-density lipoprotein (LDL), and diabetes (Deutscher et al. 1984, Lindroos et al. 1994, 
Stewart et al. 1997). Metabolic syndrome is also an independent risk factor for aortic valve 
calcification (Katz et al. 2006). Even though all these factors are also associated with 
atherosclerosis, only half of AVS patients present with significant coronary artery disease at 
angiography (Otto et al. 1997). Uncommon risk factors of AVS comprise renal insufficiency, 
Paget’s disease, primary hyperparathyroidism, and alcaptonuric ochronosis (Freeman et al. 
2004, Steger 2011). 
  
Genetics 
Several genetic factors have been suggested to predispose to CAVD. The identified genes 
include vitamin D receptor (Ortlepp et al. 2001), estrogen receptor alpha, and transforming 
growth factor beta (TGF-β) (Nordstrom et al. 2003), as well as apolipoprotein E (Avakian et al. 
2001, Novaro et al. 2003), although the latter has generated contradictory reports (Ortlepp et 
al. 2006). In addition, mutations in NOTCH1 gene have been associated with the development 
of bicuspid aortic valves as well as valvular calcification in adulthood (Garg et al. 2005). 
Bicuspid valves predisposing to AVS may be an inherited trait, and it has also been suggested 
that calcific stenosis of the trileaflet aortic valve could show familial aggregation (Probst et al. 
2006). Interestingly, angiogenesis has also been implicated: a variation in the angiogenic 
vascular endothelial growth factor A (VEGF-A) gene may associate with AVS (Zhao et al. 2012). 
Recently, a large genomewide study has identified one single-nucleotide polymorphism, or 
SNP, in the lipoprotein(a), or Lp(a), locus as a significant risk factor for aortic valve calcification 
and valve replacement surgery (Thanassoulis et al. 2013). The physiological function of Lp(a) is 
still unknown, but high serum Lp(a) levels are a risk factor for other cardiovascular diseases, 
and a causal effect to atherosclerosis has been proposed (Tsimikas and Hall 2012). 
 
 
2.2. Diagnosis and clinical course 
 
A suspicion of AVS usually rises upon clinical examination when auscultation reveals a harsh 
systolic parasternal murmur on both sides of the sternum radiating to the neck. A stenotic 
aortic valve obstructs blood flow through the aortic opening, causing increased ventricular 
pressure and decreased aortic pressure, i.e. transaortic pressure gradient. Increased effort is 
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required to maintain sufficient blood circulation, leading to left ventricular hypertrophy 
sometimes detectable as increased voltage and a strain pattern in the ECG. A chest X-ray may 
reveal the calcification of the aortic valve, most apparent in the lateral view. The presence of 
symptoms, such as shortness of breath, chest pain, or collapses already indicates 
hemodynamically severe AVS, and the need for immediate echocardiographic evaluation and 
treatment. In indefinite cases, symptoms of AVS can be provoked with exercise testing. In 
severe stenosis, a narrow aortic opening area can cause acquired von Willebrand factor 
deficiency by shear stress-induced cleavage of high-molecular-weight multimers (Loscalzo 
2012). The subsequent gastrointestinal angiodysplasia and bleeding, called Hayde’s syndrome, 
usually resolves upon valve replacement. 
 
Echocardiography reveals not only aortic valvular anatomy and calcification, but also the 
degree of stenosis, which is graded from mild (aortic valve area, or AVA, 1.5-2.0 cm
2
, mean 
transaortic pressure gradient <25 mmHg) to moderate (AVA 1.0-1.5 cm
2
, pressure gradient 25-
40 mmHg) to severe (AVA <1cm2, pressure gradient >40mmHg). Echocardiography also 
provides information on left ventricular function, which is important in evaluating the patient’s 
prognosis and thus, the timing of surgical treatment. The need for simultaneous coronary 
artery bypass surgery is detected by coronary angiography. AVS usually develops during a long 
period of time, but the prognosis rapidly deteriorates after the stenosis has become severe. If 
left untreated, AVS ultimately leads to heart failure and a significant risk of cardiac sudden 
death. The first-year survival rate of patients with hemodynamically severe AVS is 60 % (Turina 
et al. 1987), and the 5-year survival rate is only 18 %, mean 5-year survival rate being less than 
2 years (Horstkotte and Loogen 1988). 
 
Interestingly, even mild AVS is associated with an increased risk of cardiovascular events. The 
underlying cause of this phenomenon remains obscure, but concurrent coronary artery disease 
and universal atherosclerosis have been suggested (Freeman and Otto 2005). In addition, aortic 
sclerosis is associated with impaired responsiveness of platelets to nitric oxide (NO), which 
might explain the increased thrombotic risk even in cases of aortic sclerosis and mild stenosis 
(Ngo et al. 2009).  
 
 
2.3. Treatment 
 
2.3.1. Surgical treatment 
 
The only curative treatment for aortic valve stenosis is surgical valve replacement. In young and 
middle-aged patients, the stenotic valve is replaced with a mechanical prosthesis, while 
biological prostheses are used mainly in patients over 70 years of age. The operative risk is 
balanced with the increased risk of sudden cardiac death, and the importance of correct timing 
in the treatment of AVS is highlighted in international guidelines (Bonow et al. 2008). B-type 
natriuretic peptide may be helpful in assessing the risk level of asymptomatic patients with 
severe AVS (Bergler-Klein et al. 2004). Operative mortality in a Finnish AVS study was 2,4 % 
within 30 days of aortic valve replacement surgery (Taskinen et al. 2008). 
 
In recent years, a new method has become available for replacing the aortic valve: 
Transcatheter aortic valve implantation can be performed either endovascularly via the 
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subclavian or the femoral artery or transapically through a small anterolateral 
minithoracotomy (Stortecky et al. 2012). Current recommended indication for this approach is 
a case of severe stenosis when major surgery is contraindicated, e.g. due to comorbidities (high 
risk, Euroscore >20%).  The procedure involves risks that still need to be managed before the 
transcatheter method can compete with traditional replacement surgery in unselected patient 
material (Desai and Bonow 2012). 
 
2.3.2. Pharmacotherapy 
 
Despite immense effort, no medical therapy has proven successful in preventing the 
progression of AVS. Many of the possible target processes of pharmacological prevention are 
early events in the development of AVS.  Thus, the natural course of AVS with a prolonged 
asymptomatic period and a rapid end-stage advancement makes the timing and effectiveness 
of any pharmacological intervention extremely challenging. Common epidemiology and several 
histopathological similarities with atherosclerosis have also driven the search for common 
pharmacotherapy. The two forms of therapy that have advanced to clinical trials are 
hydroxymethylglutaryl coenzyme-A inhibitors (statins) and angiotensin-targeting medications, 
angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB).  
 
Statins seemed to be promising candidates in retrospective and prospective observational 
analyses (Moura et al. 2007, Rosenhek et al. 2004). Regrettably, they proved ineffective in 
reducing AVS progression in randomized, controlled trials (Chan et al. 2010, Cowell et al. 2005, 
Rossebo et al. 2008). The result remained similar in a subpopulation of patients with only mild 
stenosis (Gerdts et al. 2010). In order to produce the desired effect, lipid-lowering possibly 
should have been initiated up to decades before detectable stenosis (Helske and Otto 2009). 
 
ACE-I therapy has been demonstrated to hinder AVS progression in a rabbit model (Ngo et al. 
2011). Retrospective studies on humans, however, have been controversial (O'Brien et al. 
2005, Rosenhek et al. 2004), and the link between overall improved survival rate of patients 
with aortic valve disease and the use of ACE-I/ARB medication is inconsistent (Ardehali et al. 
2012, Nadir et al. 2011). A recent prospective follow-up study found a relationship between 
ACE-I/ARB therapy and a slower progression of tricuspid aortic valve sclerosis (Sverdlov et al. 
2012a), but the results of ongoing prospective clinical trials on AVS patients remain to be seen. 
Nevertheless, adequate pharmacological treatment of cardiac risk factors is important in order 
to prevent concurrent coronary artery disease in patients with AVS (Bonow et al. 2008). 
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Figure 2. Schematic illustration presenting the cross sections of a normal and a stenotic aortic 
valve leaflet. 
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3.1. Overview 
 
AVS was previously called “degenerative” aortic valve stenosis, separating it from the formerly 
common infective forms of the disease, such as rheumatic valve disease. Nowadays the 
metabolically active nature of AVS is acknowledged, and the term “degenerative” is no longer 
valid. The pathogenesis of AVS is characterized by endothelial injury and the subsequent 
infiltration of lipids and inflammatory cells into the valves (Olsson et al. 1994a, Otto et al. 
1994). These early events result in the proliferation and transformation of valvular interstitial 
cells, extensive extracellular matrix remodeling, active calcification, and even bone formation 
(Mohler et al. 2001, O'Brien et al. 1995). The major pathological changes in AVS are introduced 
in Figure 2, and further discussed below. Valvular neovascularization is described in detail in 
Section 4.3 (Angiogenesis and lymphangiogenesis in the aortic valve and in vascular disease). 
 
Similarities and dissimilarities between AVS and atherosclerosis 
Investigations targeted at unraveling the pathobiology of AVS have mostly followed the 
footsteps of atherosclerosis research. Indeed, many of the key cell types and molecules 
regulating inflammation and extracellular matrix remodeling in arterial atherosclerotic plaques 
have also been identified in stenotic valve leaflets. However, the severity of aortic stenosis has 
been found to specifically associate with local calcification in the aortic valve rather than that in 
the coronary arteries or the aorta (Dweck et al. 2013). 
 
One of the culprits in both atherosclerosis and AVS is the myofibroblast. In atherosclerotic 
lesions, myofibroblasts initially derive from medial smooth muscle cells (Hinz et al. 2007, Libby 
and Theroux 2005), whereas in aortic valve leaflets they transdifferentiate from the local 
resident cell, the valvular interstitial cell, which is also able to assume mesenchymal and 
osteoblast phenotypes (Liu A. C. et al. 2007, Olsson et al. 1994b). More distinct dissimilarities 
also exist. For one, the strong causal effect of lipids demonstrated in coronary atherosclerosis 
has not been replicated in AVS (Helske and Otto 2009). Furthermore, there are differences in 
the clinical manifestations of these two diseases. Atherosclerotic changes can restrict blood 
flow in the affected artery either chronically due to the development of a fibrotic, calcified 
plaque or acutely by sudden rupture of an unstable plaque, even without a preceding arterial 
obstruction (Libby and Theroux 2005). In stenotic aortic valve leaflets, no acute event similar to 
plaque rupture occurs, but chronic fibrotic and calcified changes make the valve stiffer, thus 
advancing the outflow obstruction. Such fibrotic histology, in turn, is usually desirable in 
arterial atherosclerosis because of its stability and susceptibility to modern pharmaceutical and 
invasive therapies. Based on these findings and the emerging knowledge of other 
pathophysiological dissimilarities, it has been established that coronary atherosclerosis and 
valvular stenosis are, in fact, separate disease entities rather than manifestations of the same 
pathology.   
 
 
3.2. Lipids, lipoproteins, and scavenger receptors 
 
The accumulation of lipids is considered one of the initiating events in valvular calcification 
(Demer 2001, Otto et al. 1994), supported by epidemiological data linking hyper-
cholesterolemia to AVS (Deutscher et al. 1984). The association between lipid accumulation 
and AVS progression has also been demonstated in the hypercholesterolemic animal models 
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introduced below, as well as in histological studies. Indeed, protein components of the 
atherogenic lipoproteins LDL and Lp(a), specifically apolipoproteins B100 and (a), as well as 
apolipoprotein E, also accumulate in valvular lesions (O'Brien et al. 1996). In contrast, the 
amount of the potentially protective apolipoprotein A1, a component of high-density 
lipoprotein (HDL), is reduced in stenotic valves as compared to controls (Lommi et al. 2011). In 
atherosclerotic plaques, oxidatively modified accumulated lipoproteins may play a central role 
by triggering pathological immune responses (Tsimikas and Miller 2011). Oxidized low-density 
lipoprotein (oxLDL) has also been identified in stenotic valve leaflets, where it colocalizes with 
inflammatory cells and calcium deposits (Olsson et al. 1999). Moreover, circulating oxLDL levels 
associate with more advanced histopathological changes of AVS (Cote et al. 2008), and small 
dense LDL particles, which are potential sources of oxLDL, associate with the progression of 
AVS (Mohty et al. 2008). 
 
OxLDL and other modified forms of LDL bind to scavenger receptors, a diverse group of 
membrane proteins and soluble proteins implicated in the pathogenesis of atherosclerosis 
(Goldstein et al. 1979, Parthasarathy et al. 1987). Scavenger receptor class A member 1 (SR-A1) 
and CD36, a class B scavenger receptor, play a role in macrophage foam cell formation 
(Stephen et al. 2010). Foam cells form when macrophages take up excess lipids, and this key 
pathogenic process in atherosclerosis has also been identified in AVS (Otto et al. 1994). 
Interestingly, the plasma levels of CD36 decrease in AVS patients with increasing myocardial 
hypertrophy (Heather et al. 2011). Lectin-type oxidized LDL receptor 1 (LOX-1), in turn, is 
expressed mainly in endothelial cells and mediates their oxLDL uptake (Stephen et al. 2010). In 
contrast to the above-listed scavenger receptors, scavenger receptor class B member 1 (SR-B1) 
is considered to be atheroprotective, since it participates in reverse cholesterol transport by 
binding HDL (Stephen et al. 2010). In addition to proinflammatory actions, scavenger receptors 
participate in numerous processes potentially involved in valvular pathology, including 
apoptosis, collagen production, and vascular smooth muscle cell proliferation (Mitra et al. 
2011, Stephen et al. 2010). The expression of these receptors in aortic valves, however, has not 
been previously demonstrated. 
 
OxLDL and scavenger receptors, especially CD36 and LOX-1, have also been implicated in 
angiogenesis, which is further described in Section 4.6 (Scavenger receptors and angiogenesis). 
The specific properties of scavenger receptors studied in this thesis are also summarized in 
Table 9 of the corresponding Results Section 2.3 (Oxidized LDL and scavenger receptors).  
 
 
3.3. Inflammation 
 
Only sparsely scattered macrophages and mast cells can be found in healthy aortic valve 
leaflets, whereas extensive accumulation of inflammatory cells is observable in the stenotic 
valves (Helske et al. 2004b, Otto et al. 1994). Infiltrates of T and B lymphocytes, activated mast 
cells and macrophage foam cells characterize the diseased leaflets (Helske et al. 2004b, Mohler 
et al. 2001, Otto et al. 1994). The number of valvular mast cells has even been linked to the 
disease progression (Wypasek et al. 2012). The recruitment of inflammatory cells into valvular 
tissue may be facilitated by neovascularization. In fact, the endothelial cells lining valvular 
neovessels express vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion 
molecule-1 (ICAM-1) (Mazzone et al. 2004), that are known for their role in the transportation 
LITERATURE REVIEW   │   21 
_____________________________________________________________________________ 
 
 
of inflammatory cells into tissues. Lymphatic vessels, a possible exit route for these cells, have 
been identified close to inflammatory cell infiltrates in stenotic aortic valves (Steiner et al. 
2010). Areas rich in inflammatory cells also express tumor necrosis factor alpha (TNF-α) and 
interleukin-1 beta (IL-1β) (Kaden et al. 2005a, Kaden et al. 2003), both of which are powerful 
proinflammatory mediators. Interestingly, TNF-α is expressed by mast cells in coronary 
atherosclerotic plaques (Kaartinen et al. 1996b), and valvular mast cells may also contain TNF-α 
(Helske et al. 2004a). By stimulating the secretion of protein-degrading enzymes, TNF-α and IL-
1β may contribute to the pathological extracellular matrix remodeling in stenotic valves (Kaden 
et al. 2005a, Kaden et al. 2003). Moreover, the expression of IL-1β along with the macrophage 
marker CD68 is increased in calcified areas of stenotic aortic valves as compared to 
macroscopically normal areas of the same valves (Nagy et al. 2011). Put together, these 
findings have led to the conclusion that inflammation is a central pathogenic process in AVS.  
 
In addition to inflammatory cells, cultured valvular interstitial cells secrete proinflammatory 
mediators, including monocyte chemotactic protein-1 (MCP-1), IL-6 and IL-8 (Helske et al. 2007, 
Helske et al. 2008, Meng et al. 2008). Several studies suggest that these cells actively 
participate in valvular inflammatory responses. First, the expression of bradykinin type-1 
receptor, a potential inflammatory modulator, is increased in AVS and its expression in valvular 
myofibroblasts can be induced by TNF-α (Helske et al. 2007). Furthermore, the complement 
system, a part of the innate immune system comprising a complex protein activation cascade, 
is activated in AVS (Helske et al. 2008). Valvular myofibroblasts express C3a receptor (Helske et 
al. 2008), which mediates the effects of a complement activation product, C3a. Consequently, 
C3a induces the secretion of proinflammatory mediators by cultured valvular myofibroblasts 
(Helske et al. 2008). The involvement of the complement system was confirmed by a proteomic 
analysis showing increased expression of C3 along with five other complement components in 
diseased areas of the valves (Matsumoto K. et al. 2012). Finally, valvular interstitial cells 
express Toll-like receptors 2 and 4, as well as several leukotriene receptors, and the stimulation 
of these receptors results in the release of proinflammatory and pro-osteogenic cytokines by 
the interstitial cells (Meng et al. 2008, Nagy et al. 2011). 
 
As a marker for systemic inflammation, C-reactive protein (CRP) has also been of interest in 
AVS research. CRP is commonly present in the stenotic aortic valves and is frequently found in 
degenerative aortic valve bioprosthesis, potentially reflecting inflammatory processes within 
the valve (Skowasch et al. 2006). Epidemiological studies have failed to connect elevated levels 
of circulating CRP to AVS patients (Novaro et al. 2007, Sverdlov et al. 2012b). CRP could, 
however, serve as a marker for the development of aortic valve sclerosis (Sverdlov et al. 
2012a), and disease progression as well as a prognosis once AVS has been diagnosed (Imai et 
al. 2008, Sanchez and Mazzone 2006). 
 
 
3.4. Calcification and bone formation 
 
Extensive calcification is a hallmark of AVS and valvular calcification even correlates with the 
patients’ prognosis (Rosenhek et al. 2000). Besides calcification, active bone formation and 
remodeling occur in the diseased valves. In fact, lamellar bone with bone marrow elements can 
be found in 12% of the stenotic valves (Mazzone et al. 2004, Mohler et al. 2001). Endochondral 
bone formation and microfractures have been identified in stenotic valves, and 
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neoangiogenesis is associated with the calcified and ossified areas of the leaflets (Mohler et al. 
2001). Targeted research has elucidated the underlying mechanisms and revealed active 
regulatory pathways of calcification and osteogenesis in the diseased aortic valves.  
 
Numerous osteogenic mediators have been identified in stenotic aortic valves, including 
osteopontin, osteocalcin, osteonectin, tenascin C, bone sialoprotein, core-binding factor 
subunit alpha-1 (Cbfa1), and bone morphogenetic proteins 2 and 4 (BMP 2/4) (Caira et al. 2006, 
Jian et al. 2001, Kaden et al. 2004b, Mohler et al. 2001, O'Brien et al. 1995, Rajamannan et al. 
2003, Srivatsa et al. 1997). Another pathway implicated in the adverse valvular matrix 
calcification of stenotic aortic valves is the altered balance between receptor activator of 
nuclear factor kappa β ligand (RANKL), its decoy receptor osteoprotegerin, and actual receptor 
RANK (Kaden et al. 2004a, Nagy et al. 2013). The overall pro-osteogenic properties of calcific 
aortic valve tissue have also been demonstrated with mesenchymal stem cells in an in vitro co-
culture study (Leskelä et al. 2006). 
 
Many of the abovementioned osteogenic factors associate with valvular inflammatory cells, 
implicating inflammation as a plausible trigger for aortic valve calcification (Mohler et al. 2001, 
O'Brien et al. 1995, Srivatsa et al. 1997). Further evidence for this notion has been provided by 
mechanistic studies on cultured valvular interstitial cells. TNF-α stimulates cultured valvular 
myofibroblasts to form calcific nodules and increases the expression of alkaline phosphatase 
and osteocalcin, both signs of a phenotypic change towards osteoblastic differentiation (Kaden 
et al. 2005c). Interestingly, the formation of such calcific nodules is also induced by oxLDL and 
BMP-2 (Mohler et al. 1999). Indeed, valvular interstitial cells are capable of osteoblastic 
differentiation through a mechanism potentially counteracted by statins (Osman et al. 2006). 
These cells also express the osteogenesis-associated factors BMP-2 and Cbfa1 in response to 
Toll-like receptor 2/4 stimulation (Meng et al. 2008). All in all, transformed osteoblastic valvular 
interstitial cells seem to play a central role in local osteogenesis (Liu A. C. et al. 2007).  
 
 
3.5. Extracellular matrix remodeling 
 
Disruption of normal extracellular matrix (ECM) structure is evident in stenotic aortic valve 
tissue. Active ECM remodeling is, indeed, a part of the pathogenesis of AVS from its initial steps 
to the detrimental outcome. Some early pathological events that require ECM degradation are 
the recruitment of inflammatory cells into tissue through the endothelial basement membrane, 
migration of proliferating valvular myofibroblasts, and neovascular sprouting (Liu J. et al. 2004). 
Furthermore, the same mechanisms may be involved in active valvular osteogenesis and bone 
remodeling, as well as in the modulation of local inflammatory responses (Liu J. et al. 2004). 
 
In AVS, valvular interstitial cells undergo myofibroblast differentiation and assume an active, 
profibrotic phenotype (Olsson et al. 1994b, Otto et al. 1994). The myofibroblasts produce 
increased amounts of ECM components, such as collagen I (Eriksen et al. 2006). At the same 
time, extensive ECM degradation accounts for the disruption of normal laminar arrangement of 
the matrix protein and proteoglycan network. Increased overall matrix turnover has been 
detected in stenotic valves (Eriksen et al. 2006), and a recent proteomic analysis revealed a 
major decrease in ECM components in calcified areas of stenotic valves, when compared to 
macroscopically healthy areas of the same valves (Matsumoto K. et al. 2012). In fact, individual 
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extracellular proteases capable of degrading matrix proteins and proteoglycans have been 
identified in stenotic aortic valves. These include members of the metalloproteinase 
superfamily (such as matrix metalloproteinases, or MMPs) as well as serine proteases 
(tryptase, chymase, and cathepsin G) (Edep et al. 2000, Helske et al. 2004b, Helske et al. 2006).  
 
Macrophages, lymphocytes, and myofibroblasts in stenotic aortic valves show increased 
expression of MMPs -1, -2, -3, and -9, MMP-9 being expressed only in the diseased valves (Edep 
et al. 2000). Tissue inhibitor of metalloproteinases-1 (TIMP-1) has also been identified in 
myofibroblasts of the diseased valves (Soini et al. 2001). The expression of MMP-1 and MMP-2 
by human aortic valve myofibroblasts increases in response to the inflammatory cytokine IL-1 
and the osteogenic mediator RANKL (Kaden et al. 2003, Kaden et al. 2005b). Moreover, TNF-α 
stimulates the expression of MMP-1 but not TIMP-1 in the myofibroblasts (Kaden et al. 2005a). 
Taken together, the local inflammatory and osteogenic environment seems to promote ECM 
degradation by myofibroblast-derived MMPs. Information on the balance between MMPs and 
TIMPs in stenotic valvular tissue is, however, somewhat inconsistent (Fondard et al. 2005). 
 
Three serine proteases – chymase, tryptase, and cathepsin G – have been shown to be locally 
produced in the aortic valve, their only valvular source being the mast cell (Helske et al. 2004b, 
Helske et al. 2006). These powerful proteases may directly degrade ECM in the valves. 
Moreover, chymase may also promote valvular fibrosis by inducing mast cell migration and 
degranulation and by generating an active form of transforming growth factor beta 1 (TGF-β1) 
(Lindstedt et al. 2001). Importantly, chymase and the neutral protease cathepsin G, which also 
exerts elastolytic activity (Boudier et al. 1991), are capable of generating angiotensin II (Ang II) 
from Ang I (Genest et al. 1983). Ang II is part of the circulating renin-angiotensin-aldosterone 
hormone system and is also produced locally in tissues where it exerts autocrine and paracrine 
effects (Weber et al. 1999). This pathway is of particular interest because of the existing 
possibilities for pharmacological intervention. Ang II e.g. induces the production of TGF-β1 by 
macrophages (Weber et al. 1999). In stenotic aortic valves, areas rich in cathepsin G-positive 
mast cells show increased fragmentation of elastic fibers as an indication of their local 
elastolytic activity (Helske et al. 2006). Interestingly, mast cell-rich areas also accumulate TGF-
β1 (Helske et al. 2006), potentially resulting from the generation of Ang II by the cathepsin G-
secreting mast cells. TGF-β1, in turn, promotes the differentiation of valvular interstitial cells 
into the more profibrotic myofibroblasts, further contributing to adverse ECM remodeling 
(Weber et al. 1999). TGF-β1 has also been linked to valvular calcification, as it associates with 
calcific areas of the stenotic valves (Jian et al. 2003), and promotes calcification in cultured 
valvular interstitial cells (Mohler et al. 1999). 
 
Besides cathepsin G, other cathepsins have also been implicated in adverse ECM remodeling in 
vascular disease. Cathepsins S and K, lysosomal cysteine proteases also capable of extracellular 
degradation, are overexpressed in atherosclerotic lesions (Liu J. et al. 2004). The expression of 
their endogenous inhibitor cystatin C, in turn, is decreased in the same pathology (Shi et al. 
1999). Accumulating evidence suggests a crucial role for the elastolytic and collagenolytic 
actions of these cathepsins in atherogenesis (Liu J. et al. 2004). The potent collagenolytic 
activity of cathepsin K enables its role in bone metabolism (Brömme et al. 1996), rendering a 
potential function for cathepsin K also in valvular calcification. Moreover, in 2009 Aikawa et al. 
demonstrated that cathepsin S-deficiency truly prevents aortic valve calcification in a mouse 
model of AVS, highlighting the importance of this particular cathepsin in valvular disease 
(Aikawa et al. 2009). Cathepsin V is an intracellular protease identified from activated 
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macrophages in atherosclerotic plaques (Yasuda et al. 2004). This potently elastolytic protease 
is also capable of degrading apolipoprotein B100, the protein component of LDL (Linke et al. 
2006). These findings suggest a role for cathepsin V in valvular disease as well. The implications 
of proteases in angiogenic processes are introduced in Section 4.2.  
 
 
3.6. Experimental animal models 
 
Several animal models of AVS have been developed to obtain valuable information on the 
underlying molecular mechanisms of valve stenosis and to connect them with clinical practice. 
Medical interventions demonstrated in these studies have, indeed, showed promise in the field 
of possible diagnostic assessment and pharmacotherapy for AVS in the future (Miller J. D. et al. 
2011, Rajamannan 2009). 
 
Rabbit models 
Early AVS has been demonstrated in cholesterol-fed New Zealand White rabbits already in the 
1980s, with changes in valvular surface endothelium (Sarphie 1985). Furthermore, changes in 
extracellular matrix production, foam cell formation and osteogenic markers have been 
identified in the same model, atorvastatin having been able to attenuate some of the 
pathological changes (Rajamannan et al. 2002). Atorvastatin has also been shown to inhibit 
calcification in Watanabe rabbits, which lack LDL receptors (LDLr
-/-
) (Rajamannan et al. 2005). 
Interestingly, valvular angiogenesis has been described in cholesterol-fed New Zealand White 
rabbits, with in vivo quantification using integrin-targeted nanoparticles and 19-fluoreine 
magnetic resonance imaging (Waters et al. 2008). In addition to histopathological findings, 
even hemodynamic changes of early AVS have been induced in these rabbits with a combined 
diet of cholesterol and excessive vitamin D (Drolet et al. 2003). Echocardiographically 
detectable changes have also been induced with vitamin D alone, and in this model ACE 
inhibitors were able to counteract most of the effect of vitamin D on valve thickening and 
calcification (Ngo et al. 2011). In some investigations, however, cholesterol and vitamin D diets 
induced calcification only in the ascending aorta rather than the aortic valve itself, questioning 
the ability of the diet models to mimic human disease (Hekimian et al. 2009). 
 
Mouse models 
Even hemodynamically severe stenosis has been demonstrated in mice lacking the receptor for 
LDL and expressing only human apolipoproteinB 100 (LDLr
-/-
apoB
100/100
) (Weiss et al. 2006). In 
fact, several mechanistic studies on mice have strengthened the role of actively regulated 
osteogenic factors, hyperlipidemia, metabolic syndrome, and angiogenesis in the pathogenesis 
of AVS (Aikawa et al. 2007, Drolet et al. 2006, Miller J. D. et al. 2010, Yoshioka et al. 2006), and 
suggested a causal role for angiogenesis in the development of AVS (Yoshioka et al. 2006). 
Furthermore, the administration of angiotensin II induces aortic valve thickening independently 
of its effect on blood pressure in apolipoprotein E-deficient mice (Fujisaka et al. 2013). Some 
evidence of the potential benefits of ACE inhibitors has been presented in a uremic mouse 
model (Simolin et al. 2009).  A major limitation in mice as an experimental model for AVS is 
their small size, which compromises the possibilities to reliably conduct extensive 
hemodynamic and histopathological analyses (Miller J. D. et al. 2011). Moreover, the effect of 
arterial atherosclerosis of the surrounding aorta and the sinuses of valsalva to the 
hemodynamic measurements of the aortic valve may not entirely be excluded.  
LITERATURE REVIEW   │   25 
_____________________________________________________________________________ 
 
 
 Angiogenesis and lymphangiogenesis 4.
 
4.1. Normal vascular development 
 
4.1.1. Overview 
 
Angiogenesis can occur by several mechanisms depending on the prevailing conditions. During 
early development, blood vessels form in a completely avascular tissue by the differentiation 
and proliferation of endothelial progenitor cells in a process called vasculogenesis. These newly 
formed blood vessels, i.e. neovessels, are then modified to meet the needs of their 
surroundings by angiogenic remodeling. Angiogenic remodeling affects all blood vessel 
components, including endothelial cells and their interactions, supporting cells, such as 
pericytes, and the surrounding extracellular matrix (Yancopoulos et al. 2000). Angiogenic 
sprouting, the prevalent type of vascular expansion, refers to a process in which new blood 
vessels sprout into tissue from existing vessels, generating a primary vascular network. This 
usually involves the destabilization of the pre-existing blood vessel, including extracellular 
matrix degradation to allow the endothelial cells to migrate and form the new vessel 
(Yancopoulos et al. 2000). New blood vessels can also split from a pre-existing vascular network 
through a process called intussusceptive angiogenesis or splitting angiogenesis (De Spiegelaere 
et al. 2012). The three mechanisms of angiogenesis are illustrated in Figure 3. In addition to 
these proliferative mechanisms, vascular regression and pruning are also vital for shaping a 
functioning vascular network. In the fully developed cardiovascular system, blood is pumped 
from the heart into the tissues via arteries and returned through the venous system. 
 
 
         
 
Figure 3. Mechanisms of angiogenesis, as described in (De Spiegelaere et al. 2012).  
A) In vasculogenesis, endothelial progenitors differentiate and form rudimentary tube 
structures that eventually mature into functional blood vessels. B) Angiogenic sprouting from 
pre-existing blood vessels is an invasive process. The endothelial tip cell with its filopodia leads 
the sprout to the surrounding tissue by e.g. secreting matrix-degrading components. 
Proliferating stalk cells follow the tip cell, forming the vessel lumen. The remaining quiescent 
endothelial cells are called phalanx cells. C) Intussusceptive angiogenesis enables the expansion 
and remodeling of an existing vascular network by splitting pre-existing capillary tubes into 
parallel structures. 
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Lymphatic vessels collect extracellular fluid, macromolecules, and cells from the cellular 
interstitial space back into the circulating blood. Lymphatic capillaries are blind-ended, with 
loose lining endothelium, little or no basement membrane, and no supporting cells. From the 
capillaries, lymph flows to collecting lymphatic vessels that are surrounded by smooth muscle 
cells and also contain valves. On the way to the lymphatico-venous junctions, lymph goes 
through lymph nodes, where antigen-presenting cells may initiate immune responses. This is 
also a well-known route for cancer metastasis, and major advances in lymphatic research have, 
indeed, been made in cancer research (Alitalo et al. 2005). 
 
4.1.2. Vascular endothelial growth factors and their receptors 
 
The best-known angiogenic growth factors are the vascular endothelial growth factors (VEGFs), 
which are also considered to be the most important factors in regulating both angiogenesis and 
lymphangiogenesis. Up to date, five members of this family have been identified in mammals: 
VEGF-A, -B, -C, and -D, and placental growth factor (PlGF) (Joukov et al. 1996, Leung et al. 1989, 
Maglione et al. 1991, Olofsson et al. 1996, Senger et al. 1986, Yamada et al. 1997). The cellular 
receptors of these growth factors are vascular endothelial growth factor receptors 1-3 (VEGFR-
1, -2, and -3) (Aprelikova et al. 1992, de Vries et al. 1992, Terman et al. 1991). The binding 
pattern of the VEGFs to their receptors is illustrated in Figure 4. The affinity of the VEGFs to 
their specific receptors may also be affected by neuropilins 1 and 2, which act as their co-
receptors (Lohela et al. 2009). 
 
 
 
Figure 4. VEGFs and their receptors as described in (Lohela et al. 2009). 
 
 
The binding of VEGFs to their receptors causes receptor dimerization, autophosphorylation, 
and activation of corresponding cellular signaling cascades. VEGFR-2 is responsible for the 
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major angiogenic effects of the VEGFs, inducing endothelial cell proliferation and migration 
(Lohela et al. 2009). It also increases vasodilatation and vascular permeability by activating 
endothelial nitric oxide synthase (Shen et al. 1999). VEGFR-1, in turn, may act as a VEGF trap, 
thus scaling down the angiogenic effects of VEGFR-2 and guiding angiogenic sprouts (Saharinen 
et al. 2010). It may also modulate VEGFR-2 signaling and increase cell recruitment via VEGFR-2. 
These effects depend at least partly on receptor heterodimerization of VEGFR-1 with VEGFR-2 
(Lohela et al. 2009). VEGFR-3 controls lymphangiogenesis during embryonic development and 
in pathological conditions later in life. In adults, the expression of VEGFR-3 mainly confines to 
lymphatic endothelium, but some angiogenic properties have also been described (Lohela et al. 
2009). Indeed, VEGFR-3 seems to be involved at least in venous sprouting and tumor 
angiogenesis (Saharinen et al. 2010). 
 
VEGF-A is clearly required for both vasculogenesis and vascular homeostasis; lack of VEGF-A is 
lethal already at the embryonic stage, and endothelial cell survival depends on autocrine VEGF-
A signaling (Lohela et al. 2009). VEGF-A binds to both VEGFR-2 and VEGFR-1, VEGFR-2 
accounting for the angiogenic effects as described above. Several isoforms of VEGF-A have 
been identified, with differences in binding to ECM components and co-receptors of the 
VEGFRs (Lohela et al. 2009). Local hypoxia, shortage of oxygen resulting from increased cellular 
metabolic load, strongly induces the expression of VEGF-A in order to enhance the defective 
blood supply (Shweiki et al. 1992). 
 
The expression of VEGF-B and PlGF varies in different tissues. The highest levels of VEGF-B can 
be found in the heart and in skeletal muscle, whereas PlGF is expressed in the placenta, the 
heart, and the lungs. Both growth factors only activate VEGFR-1 (Lohela et al. 2009), resulting 
in corresponding modulatory effects. 
 
VEGF-C and VEGF-D act through VEGFR-3, and are, thus, lymphangiogenic (Lohela et al. 2009). 
VEGF-C is first synthesized as a precursor, and the generation of active VEGF-C from a 
dimerized propeptide requires both intracellular and extracellular proteolytic modification 
(Joukov et al. 1997). These modifications increase the affinity of VEGF-C to VEGFR-3 and enable 
the binding of VEGF-C to VEGFR-2. The most processed form, in which the disulfide bonds of 
both N- and C- terminal peptides are cleaved (VEGF-CΔNΔC), activates VEGFR-2 equally to VEGF-
A at 4- to 5-fold concentrations (Joukov et al. 1997). Correspondingly, the activation of VEGFR-2 
by VEGF-A or VEGF-CΔNΔC stimulates endothelial cell invasion and tube formation in vitro (Tille 
et al. 2003). The posttranslational processing of VEGF-D is similar to that of VEGF-C, as the 
mature form of VEGF-D is able to activate VEGFR-2 in addition to VEGFR-3 (Achen et al. 1998). 
In fact, the angiogenic activity of the processed form of VEGF-D may even surplus that of VEGF-
A at high expression levels, as demonstrated in an adenoviral gene transfer model in rabbits 
(Rissanen et al. 2003). 
 
Other angiogenic growth factors with established roles in angiogenic sprouting and remodeling 
are the angiopoietins and ephrins, and their respective receptors Ties and Ephs. Angiopoietin-1 
participates in maintaining the stability of mature blood vessels, whereas angiopoietin-2 may 
act as a de-stabilizing signal initiating angiogenic remodeling (Yancopoulos et al. 2000). Ephrins, 
in turn, are linked to the interactions of arterial smooth muscle and endothelial cells 
(Yancopoulos et al. 2000). Nevertheless, the VEGFs remain the most critical initiating factors for 
both vasculogenesis and angiogenic sprouting.  
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4.1.3. Angiogenic remodeling and vascular sprouting 
 
Following vasculogenesis, the maturing of primary vasculature into functioning capillaries 
involves several changes in the vessel wall. The blood vessels enlarge, endothelial cells 
integrate, assume a quiescent phenotype, and become covered with supporting cells, such as 
pericytes in capillaries and postcapillary venules, and smooth muscle cells in arterioles and 
larger arteries (Allt and Lawrenson 2001, Yancopoulos et al. 2000). The supporting cells provide 
stability to the blood vessel by regulating endothelial cell function and by secreting reinforcing 
ECM structures. Also, by secreting TGF-β, pericytes inhibit endothelial cell growth and 
migration, thus inhibiting angiogenic sprouting. Accordingly, the loss of pericytes leads to 
uncontrolled capillary proliferation and microaneurysms (Allt and Lawrenson 2001). Arterioles 
and larger arteries are even more organized, consisting of three distinct layers: a thin luminal 
intima, a medial layer of contractile smooth muscle cells and elastic ECM, and an outer 
adventitial layer of loose connective tissue. In addition to structural support, the contractile 
smooth muscle cell layer enables the local and hormonal control of blood flow, adjusting the 
delivery of oxygen and nutrients into tissues in demand.  
 
The organized structures described above need to be disrupted for angiogenic sprouting to 
occur. Importantly, the local sustained inflammation observed already in early sclerotic aortic 
valve lesions could serve as a trigger for an angiogenic response (Arroyo and Iruela-Arispe 
2010). Inflammatory cytokines, including TNF-α and MCP-1, enhance vascular permeability, 
which, in turn, allows for both inflammatory and endothelial cell migration (Arroyo and Iruela-
Arispe 2010).  
 
Endothelial tip cell activation is the first step of angiogenic sprouting, and VEGF-A ia a crucial 
promoting factor in this process. In fact, VEGF-A and -C induce endothelial cell migration via 
VEGFR-2 and -3 expressed by the tip cells (Lohela et al. 2009). Furthermore, the balance 
between VEGFs, angiopoietins, and ephrins seems to be central in regulating vascular stability 
and permeability, as well as in inhibiting excessive angiogenesis (Yancopoulos et al. 2000). In 
addition to VEGF signaling, regulation of the periendothelial ECM also plays a role in the 
angiogenic activation of endothelial tip cells, collagen I being a potent angiogenic component 
and laminin 1 its counteractor (Davis and Senger 2005). To invade the surrounding tissue, 
endothelial tip cells secrete ECM-degrading proteases, including MMPs -2, -3, and -9 also found 
in stenotic aortic valves (Arroyo and Iruela-Arispe 2010, Edep et al. 2000). Furthermore, 
inflammatory cells participate in the angiogenic invasion by secreting proteases that both 
degrade ECM and cleave the VEGFs into their active forms (Arroyo and Iruela-Arispe 2010).  
 
Proliferating stalk cells follow the tip cell, forming the vessel lumen. The commitment of stalk 
cells to tip cell phenotype is inhibited by the tip cell via NOTCH1-mediated downregulation of 
VEGFR- and -3 (Lohela et al. 2009). In addition to the locally proliferating cells, circulating 
endothelial progenitors may also contribute to vascular sprouting (Urbich and Dimmeler 2004). 
Again, VEGF may play a role in mobilizing these cells from the bone marrow to areas of active 
neovascularization (Costa et al. 2007). Regression of the newly formed capillaries follows the 
resolution of the inflammatory response (Arroyo and Iruela-Arispe 2010). In many pathological 
conditions, however, chronic inflammation maintains the vascular network, and the primary 
sprouts may mature to organized vessels (Costa et al. 2007). 
 
LITERATURE REVIEW   │   29 
_____________________________________________________________________________ 
 
 
4.1.4. Lymphatic vessel development and sprouting 
 
Lymphatic vessels arise from the venous system during early embryonic development. 
Transformed vascular endothelial cells expressing VEGFR-3, the homeobox transcription factor 
PROX-1 and Lymphatic vascular endothelial hyaluronan receptor (LYVE-1) emerge in the 
cardinal vein. This lymphatic commitment results in the formation of primary lymph sacs that 
continue maturing into lymphatic capillaries and collecting structures (Karpanen and Alitalo 
2008). The predominant pathway in lymphatic vessel growth is the activation of VEGFR-3 by 
VEGF-C and -D (Alitalo et al. 2005). In addition, several co-receptors as well as interplay 
between angiogenic growth factors, such as VEGF-A and angiopoietin-1, have been identified 
to be involved in lymphangiogenesis (Alitalo et al. 2005). In adults, lymphatic vessel growth 
follows the angiogenic response in physiological and pathological conditions, such as wound 
healing, tumor growth and inflammation, but the exact origin of lymphatic sprouts in these 
conditions remains unclear (Karpanen and Alitalo 2008). Nevertheless, the proinflammatory 
cytokines IL-1β and TNF-α may play a role in inflammation-induced lymphangiogenesis, as they 
are able to induce the production of VEGF-C by human lung fibroblasts (Ristimaki et al. 1998). 
 
Lack of lymphatic vasculature leads to interstitial fluid and protein accumulation. The chronic 
stage, lymphedema, results in dermal fibrosis, an increase in adipose and connective tissue, 
and impaired wound healing and immune defense in the affected area (Karpanen and Alitalo 
2008). Remarkably, compensating lymphatic vasculature has been successfully grown in 
experimental models using a VEGFR-3-specific form of VEGF-C (Karpanen and Alitalo 2008), 
highlighting the importance of this potent lymphangiogenic growth factor. 
 
 
4.2. Proteases in angiogenesis and lymphangiogenesis 
 
A variety of proteases participate in the modulation of periendothelial and extracellular matrix 
involved in angiogenic sprouting and vascular remodeling. The proteolytic degradation of ECM 
not only clears the way for the emerging angiogenic sprouts but also modulates angiogenesis 
by releasing fragments from ECM components and by inducing conformational changes in 
some ECM proteins (Bellon et al. 2004). Among the generated fragments, called matrikines, are 
plasminogen-derived angiostatin, endostatin cleaved from collagen XVIII, and several non-
collagenous domains of type IV collagen, all of which are considered anti-angiogenic (Bellon et 
al. 2004). Remarkably, excess endostatin has also been shown to hinder tumor 
lymphangiogenesis in mice (Brideau et al. 2007). Angiostatin can be converted from 
plasminogen by elastase and by MMP-3, -7, and -9 (Bellon et al. 2004), whereas endostatin is 
generated by elastase, several MMPs, and cathepsins, including MMP-3, MMP-9, and cathepsin 
K (Ferreras et al. 2000). Some MMPs, such as MMP-1 and -10, even seem to be involved in 
vascular regression rather than mere angiogenic modulation (Arroyo and Iruela-Arispe 2010).  
 
In contrast to the abovementioned antiangiogenic actions, MMP-3 and -9 also promote 
angiogenesis by modulating VEGF-A to its more angiogenic forms (van Hinsbergh et al. 2006). 
Furthermore, proteolytically cleaved fragments of collagen I, collagen IV, and elastin attract 
inflammatory cells and are subsequently able to induce the expression of various proteases 
and cytokines (Arroyo and Iruela-Arispe 2010), thus indirectly promoting both angiogenesis and 
lymphangiogenesis. More specifically, neutral elastolytic proteases, including MMP-2, MMP-9, 
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and cathepsin G, have been speculated to promote angiogenesis by generating such fragments 
from intact elastin (Bellon et al. 2004). Some cathepsins even seem to be crucial for 
angiogenesis. This has been demonstrated in cathepsin S-deficient mice that showed 
decreased endothelial cell invasion capacity, as well as defective microvessel growth, during 
wound repair (Shi et al. 2003). Indeed, loss of cathepsin S activity in mice lacking LDL receptor 
resulted in reduced neovascularization in atherosclerotic lesions as well (Liu J. et al. 2004). 
  
Lymphatic capillary endothelium lacks a proper basement membrane and is attached to its 
surroundings by loose anchoring filaments composed mainly of elastic fibers. Nevertheless, the 
proteolytic processes involved in lymphatic endothelial cell migration resemble those in 
angiogenic sprouting (Ji 2006). Importantly, the intracellular and extracellular proteolytic 
processing of VEGF-C and -D is essential for both their lymphangiogenic and angiogenic actions 
(Achen et al. 1998, Joukov et al. 1997). 
 
 
4.3. Angiogenesis and lymphangiogenesis in the aortic valve 
 
In studies using injection techniques to identify vascular structures, blood vessels have been 
infrequently identified in healthy human aortic valve leaflets, while lymphatic vessels have 
been completely absent (Johnson and Blake 1966). In stenotic valve leaflets, neovessels have 
been consistently detected, and angiogenesis has been recognized as a potential pathological 
process contributing to the progression of AVS (Mazzone et al. 2004, Soini et al. 2003). 
Neoangiogenesis has even been suggested to be the initiating trigger of AVS (Hakuno et al. 
2009).  
 
Neovessels can be seen in up to 85 % of the stenotic valve samples, and they correlate with 
valvular inflammatory cells and calcium content (Mazzone et al. 2004). In fact, blood vessels 
particularly manifest themselves adjacent to cell-rich and calcific areas, but also close to valve 
surface (Charest et al. 2006). Abundant neovessels in cellular islets together with the presence 
of endothelial progenitor cells implicate that vasculogenesis occurs in the stenotic aortic valves 
(Charest et al. 2006). Valvular neovessels have also been speculated to originate from existing 
arteries of the aorta, i.e. the vasa vasorum, and by budding from valvular surface endothelium 
(Charest et al. 2006, Steiner et al. 2010).  
 
Like angiogenesis, lymphangiogenesis has been linked to the pathogenesis of atherosclerosis 
(Nakano et al. 2005). Even though the role of lymphatics in valvular disease was speculated 
already in the 1980s (Miller A. J. 1982), lymphatic vessels were immunohistochemically 
detected from stenotic aortic valves only recently, and their role in valvular pathology is 
unclear (Kholova et al. 2011, Steiner et al. 2010). 
 
 
4.4. Local modulators of angiogenesis and lymphangiogenesis in aortic 
valves 
 
Inflammation being an important trigger for angiogenic sprouting (Arroyo and Iruela-Arispe 
2010), the infiltration of inflammatory cells and the ensuing hypoxia from the rapidly increasing 
cellular metabolic load could launch an angiogenic response in the normally avascular valve 
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leaflets. Furthermore, the identified extensive mechanisms of ECM remodeling provide a 
favorable environment for angiogenic sprouting. In addition to these pathological events, 
several specific local mechanisms potentially contribute to valvular angiogenesis.  Table 1 
summarizes potential antiangiogenic and proangiogenic players identified in aortic valves.  
Detailed descriptions and corresponding references are provided in the text below and in 
Sections 3.5 (Extracellular matrix remodeling), and 4.2 (Proteases in angiogenesis and 
lymphangiogenesis). 
 
Table 1.  Factors potentially involved in valvular angiogenesis. These mediators may contribute 
to valvular angiogenesis by different mechanisms: VEGFs strongly affect endothelial cell (EC) 
migration and survival, whereas MMPs and cathepsins may exert both anti- and proangiogenic 
effects by ECM degradation and proteolytic processing. In addition, some literature-based 
potential contributors of valvular angiogenesis are shown in grey. Links to corresponding thesis 
substudies are also denoted. Arrows indicate observed changes in AVS. 
 
Mechanism Antiangiogenic Angiogenic 
EC migration  Endostatin (↑) (II)  VEGF-A (via VEGFR-2 ↑) (II) 
and/or survival Chondromodulin I ↓ Inflammation (e.g. TNF-α, MCP-1 ↑) (II-IV)  
 
TGF-β ↑ Elastin (proteolytically processed) 
 
Thrombospondin-1 ↔ VEGFs -C and -D (III) 
 
Angiopoietin-1 Angiopoietin-2 
 
Laminins Collagen I 
  
Cathepsin S (I) 
ECM degradation TIMP-1 ↔ MMP-2, -3, and -9 (macrophages, myofibroblasts) ↑ 
(expressing cells) Thrombospondin-2 ↑ Tryptase, chymase, Cathepsin G (mast cells) ↑ 
  
Other cathepsins (I) 
Proteolytic MMP-3 and -9 ↑ (endostatin) MMP-3 and -9 ↑ (VEGF-A) 
processing MMP-3 ↑ (osteonectin) MMP-3 ↑ (osteonectin) 
(target molecule) Cathepsin K (endostatin) (I) MMP-2 and -9, cathepsin G ↑ (elastin) 
Other Osteonectin ↑ Osteonectin ↑ 
  
Angiotensin II ↑ 
  
LRP5 ↑ 
  
OxLDL ↑ (scavenger receptors) (IV)  
 
 
VEGF-A has been detected in stenotic aortic valves, and its receptors VEGFR-1 and VEGFR-2 are 
expressed by valvular endothelial and interstitial cells (Soini et al. 2003). In addition, the 
VEGFR-2 positivity of valvular interstitial cells correlates positively with valvular blood vessel 
density (Soini et al. 2003). Osteonectin (aka SPARC; secreted protein, acidic and rich in 
cysteine) is also associated with blood vessels in stenotic aortic valves, being altogether absent 
from healthy leaflets (Charest et al. 2006).  Traditionally, osteonectin is a mineralization-
promoting glycoprotein secreted by osteoblasts (Termine et al. 1981), but it also has pro- and 
antiangiogenic effects (Bellon et al. 2004). Notably, serine proteases and cathepsins can cleave 
angiogenic fragments from the intact protein (Iruela-Arispe et al. 1995). One of the proteases 
involved in generating these modulatory peptides is MMP-3 (Sage et al. 2003), which is 
upregulated in AVS (Edep et al. 2000). Osteonectin can also induce the expression of MMP-9 
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(Bradshaw 2012), and indeed, osteonectin and MMP-9 colocalize in stenotic valves, mainly in 
the areas of neovascularization (Charest et al. 2006). 
 
In addition, other potentially angiogenic factors with less evident association to valvular 
neovascularization have been detected in stenotic aortic valves. Upregulation of the low-
density lipoprotein receptor-related protein 5 (LRP5) pathway may contribute to bone 
formation in stenotic aortic valves (Caira et al. 2006), but the same protein has also been linked 
to capillary maturation (Xia et al. 2008). Furthermore, angiotensin II-producing systems are 
upregulated in AVS (Helske et al. 2004b). Since Ang II is able to induce VEGF-A expression in 
cardiac microvascular endothelial cells (Fujiyama et al. 2001), we may surmise that the locally 
generated Ang II also possesses some angiogenic potential in the diseased valves. 
 
The proangiogenic environment in stenotic aortic valves may also depend on the suppression 
of local antiangiogenic factors. Convincing evidence from an aging mouse model as well as 
human samples and cell culture experiments suggests that chondromodulin-I prevents 
angiogenesis in healthy valve leaflets and that its downregulation is involved in valvular 
angiogenesis (Yoshioka et al. 2006). Indeed, VEGF-A-expressing areas of human diseased 
leaflets show increased vascular densities and diminished chondromodulin-I positivity 
(Yoshioka et al. 2006). Another antiangiogenic molecule detected from stenotic valve tissue is 
the collagen XVIII-derived matrikine endostatin, which inhibits angiogenesis by e.g. 
counteracting VEGF-A-induced endothelial cell migration (Bellon et al. 2004, Chalajour et al. 
2004). In contrast to the upregulation of proangiogenic and downregulation of antiangiogenic 
factors described above, certain antiangiogenic mechanisms seem to be induced in AVS. The 
expression of thrombospondin-2, an intracellular protein involved in MMP degradation and 
inhibition of angiogenesis, is increased in AVS (Pohjolainen et al. 2012). As several MMPs are 
also upregulated in AVS, the compensatory actions of thrombospondin-2 may be insufficient in 
controlling the proangiogenic actions of the MMPs (Edep et al. 2000, Pohjolainen et al. 2012). 
 
In contrast to the identified mechanisms of angiogenic regulation described above, the list of 
specific factors potentially promoting lymphangiogenesis in stenotic aortic valves is still short. 
In addition to the general ECM destruction and remodeling, the only pro-lymphangiogenic 
factor detected from stenotic aortic valves is macrophage-derived TNF-α (Kaden et al. 2005a). 
However, potential candidates can be found in atherosclerotic plaques, where e.g. VEGF-D 
expression decreases in complicated lesions, and the remaining VEGF-D localizes to areas of 
neovascularization (Rutanen et al. 2003). Thus, examining the expression of lymphangiogenic 
growth factors in AVS could uncover previously unrecognized disease-altering mechanisms. 
 
4.5. Angiogenic potential of mast cells 
 
Mast cells are inflammatory cells that store histamine, neutral proteases and inflammatory 
cytokines in heparin-rich granules that are released into the surrounding tissue upon mast cell 
activation. Mast cells are consistently found close to small blood vessels and lymphatic vessels, 
the former having been demonstrated in atherosclerotic plaques as well (Kaartinen et al. 
1996a). In fact, a role for mast cells has been proposed in the pathological angiogenesis 
associated with atherosclerosis, abdominal aortic aneurysms, obesity, and cancer (Ribatti and 
Crivellato 2011, Xu and Shi 2012). Mast cells also contribute to lymphangiogenesis in cancer, 
and cultured mast cells secrete lymphangiogenic growth factors (Detoraki et al. 2009, Ribatti 
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and Crivellato 2011). However, the link between mast cells and lymphangiogenesis has 
remained unestablished in atherosclerotic diseases. 
 
In addition to the proteolytic ECM degradation required in angiogenic sprouting, mast cells can 
participate in angiogenesis by secreting VEGF-A and a wide variety of other angiogenic 
mediators including growth factors, agents increasing vascular permeability, proteases that 
release growth factors from ECM, and chemokines attracting macrophages and lymphocytes 
(Grützkau et al. 1998, Norrby 2002). In stenotic aortic valves, activated mast cells secrete ECM-
degrading tryptase, and also chymase and cathepsin G, which, in addition to being capable of 
degrading ECM, are also able to generate the angiogenic effector angiotensin II (Helske et al. 
2004b, Helske et al. 2006). Even though VEGF-A has been detected in endothelial cells and 
myofibroblasts in stenotic aortic valves (Soini et al. 2003), and mast cells in other tissues have 
been found to contain VEGF-A (Grützkau et al. 1998), the ability of valvular mast cells to 
produce this potent angiogenic factor is unknown.  
 
 
4.6. Scavenger receptors and angiogenesis  
 
Both antiangiogenic and proangiogenic actions of oxLDL on vascular endothelial cells have been 
described; oxLDL may inhibit endothelial cell proliferation but it also induces capillary tube 
formation (Chen et al. 2000, Dandapat et al. 2007, Yu et al. 2011). The inhibitory effects seem 
to result from downregulation of another angiogenic molecule, basic fibroblast growth factor 
(Chen et al. 2000). The increase in capillary tube formation, in turn, was first linked to LOX-1-
mediated VEGF-A upregulation (Jiang et al. 2011). More recently, a vast range of genes 
involved in cell adhesion, migration, and angiogenesis were found to be regulated by oxLDL via 
LOX-1 (Khaidakov et al. 2012), consolidating the role of this scavenger receptor in the 
angiogenic actions of oxLDL. Intriguingly, one of the proangiogenic properties of angiotensin II 
is its ability to induce LOX-1 expression (Hu et al. 2007). 
 
The class B scavenger receptor CD36 has a variety of functions in the immune system, and it is 
centrally involved in macrophage foam cell formation in atherosclerosis (Stephen et al. 2010). 
In contrast to LOX-1, the angiogenic actions of CD36 seem to be independent of oxLDL. In 
endothelial cells, CD36 mediates apoptotic signals of thrombospondins-1 and -2. Furthermore, 
thrombospondin-1 inhibits endothelial cell migration via CD36, thus inhibiting angiogenesis 
(Lawler and Lawler 2012). Notably, thrombospondin-1 has been detected from stenotic aortic 
valves, but unlike thrombospondin-2, its expression levels remain unchanged in AVS 
(Pohjolainen et al. 2012). CD36 is also involved in the thrombospondin-induced inhibition of 
endothelial cell nitric oxide synthase pathway, thus counteracting the effects of VEGF-A on 
vascular permeability (Lawler and Lawler 2012). Moreover, CD36 has been linked to 
thrombospondin-1-mediated decrease in VEGF-C and inhibition of lymphangiogenesis in mice 
(Cursiefen et al. 2011), suggesting that CD36 may also mediate antilymphangiogenic signals. 
 
Ligands for both LOX-1 and CD36 have been identified in stenotic aortic valves (Olsson et al. 
1999, Pohjolainen et al. 2012), as well as factors potentially inducing their expression, including 
angiotensin II and endothelin-1 (see Results, Table 9) (O'Brien et al. 2002, Peltonen et al. 
2009b, Stephen et al. 2010). The expression of these scavenger receptors capable of 
modulating valvular angiogenesis has remained, however, an unstudied area of AVS research. 
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III AIMS OF THE STUDY 
 
 
The aim of this thesis was to investigate angiogenesis and lymphangiogenesis in aortic valve 
stenosis. The substudies focused on different steps of vascular remodeling, as well as the 
possible role of valvular mast cells and myofibroblasts along with their interactions. The 
following specific questions were addressed: 
 
 
1) Are the elastolytic cathepsins S, K, and V, and their inhibitor cystatin C, expressed in 
stenotic aortic valves, and could they be involved in valvular neovascularization? (I) 
 
2) Are mast cells involved in valvular neoangiogenesis and lymphangiogenesis, and could 
the interplay between mast cells and valvular myofibroblasts contribute to these 
processes? (II-IV) 
 
3) Are lymphangiogenic growth factors expressed in the aortic valve, and could changes 
in their expression play a role in AVS? (III) 
 
4)  Are scavenger receptors SR-A1, SR-B1, CD36, and LOX-1 expressed in the aortic valve, 
and may changes in their expression affect valvular neovascularization? (IV) 
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IV MATERIALS AND METHODS 
 
 
The methods used in this thesis are summarized in Table 2. The methods are briefly described 
here, and detailed descriptions of all the methods including supplementary references are 
provided in the original publications. 
 
 
Table 2. Methods used in Studies I-IV. 
Method Study Reference 
Collection and preparation of tissue material I-IV   
Histological stainings (Elastic van Gieson stain) I   
Immunohistochemistry and double immunofluorescence I-IV (Helske et al. 2004b) 
Confocal microscopy II   
Computer-assisted morphometry I-III (Helske et al. 2006) 
Fluorometric detection of cathepsin activity I (Werle et al. 1999) 
Polymerase chain reaction (PCR) and semi-quantitative PCR I-II (Helske et al. 2004b) 
Quantitative real-time PCR (qPCR) I, III-IV (Livak and Schmittgen 2001) 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) to detect endostatin degradation 
II (Laemmli 1970) 
Isolation, culture and stimulation of human aortic valve 
myofibroblasts 
II-IV (Helske et al. 2007) 
LAD2 cell culture and activation II (Kirshenbaum et al. 2003) 
Human peripheral blood-derived mast cell culture and 
activation 
II-IV (Lappalainen J. et al. 2007) 
Enzyme immunoassays II-IV   
Isolation and oxidation of LDL IV (Havel et al. 1955) 
Protein quantitation with Lowry IV (Lowry et al. 1951) 
Measurement of thiobarbituric acid-reactive substances 
(TBARS) as a means to determine the degree of LDL oxidation 
IV (Hessler et al. 1983) 
Cellulose acetate electrophoresis (CAE) of lipoproteins  
as a means to determine the degree of LDL oxidation 
IV  
Statistical analyses  I-IV   
 
 
Clinical material (I-IV) 
The study population used in this thesis is characterized in Tables 3 and 5. Different 
subpopulations were used in each study, and they are further described in the original articles. 
The number of valves used in each analysis is denoted in the text. A total of 95 stenotic aortic 
valves were obtained at valve replacement surgery due to symptomatic, isolated AVS. We 
excluded patients with moderate to severe aortic regurgitation, mitral valve disease, a history 
of myocardial infarction, significant (>50 %) proximal coronary artery stenosis, complicated 
diabetes, renal insufficiency (serum creatinine >170 µmol/l), endocarditis, or malignancy. 
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Control material was collected from patients undergoing cardiac transplantation, valve 
replacement surgery due to aortic valve regurgitation, or from deceased organ donors whose 
hearts were unsuitable for use as grafts due to advanced age or suspected ischemia. Only 
macroscopically and microscopically healthy valves were accepted as controls, and samples 
with mild calcification were considered sclerotic. Typical causes of death in the organ donor 
group were brain trauma (n=9) and spontaneous intracerebral hemorrhage. Diagnoses leading 
to heart transplantation were dilated cardiomyopathy (n=11) and ischemic cardiomyopathy 
(n=4). Aortic valve regurgitation (AVR) was evaluated as moderate to severe at the time of 
surgery. The study complies with the declaration of Helsinki, and the protocol was approved by 
the Ethics committee of Helsinki University Central Hospital (approval ref. nr. 557/E5/02, clause 
nrs. 88/1999, 549/2002, 382/2005, and 141/13/03/01/10 for AVS and AVR material; approval 
ref. nr. 264/E06/05 for transplant and organ donor material). All the patients signed an 
informed consent, and the use of organ donor tissue was approved by The National Authority 
for Medicolegal Affairs of Finland (approval ref. nr. 4444/32/300/05). 
 
 
Table 3. Characteristics of all the patients and control subjects included in the 
immunohistochemical analyses and PCR analyses in Studies I-IV. Data are presented as mean ± 
SD (range) or number of patients (%). 
 
    
AVS patients 
(n=95) 
Organ donors 
(n=23) 
Transplants 
(n=15) 
AVR 
(n=6) 
Age (years) 67 ± 10  
(39-86) 
57 ± 7  
(43-68) 
52 ± 11  
(27-62) 
66 ± 9 
(55-79) 
Sex, male/female 46/49 12/8 13/2 5/1 
NYHA class, 1/2/3/4 4/58/28/2     1/3/2/0 
Aortic valve area (cm
2
) 0.67 ± 0.18  
(0.3-1.1)       
Mean pressure gradient (mmHg) 49 ± 16 (14-95)       
Number of cusps, 2/3/4 13/75/1* 1/22/0 0/15/0 0/6/0 
Smoking, No/Ex-smoker/Current 60/20/15 ?/?/8 6/4/0 4/2/0 
Diabetes   5 (5%)     2 (33%) 
Hypertension 32 (34%)     5 (83%) 
LDL cholesterol (mmol/l) 3.1 ± 0.9  
(1.3-5.0)       
Medication ACE-I/ARB 24 (25%) 1 (13%)** 15 (100%) 3 (50%) 
 β-blocker 58 (61%) 2 (25%)** 12 (80%) 3 (50%) 
 Diuretic 32 (34%) 0 (0%)** 15 (100%) 4 (67%) 
 Statin 22 (23%) 0 (0%)** 4 (27%) 0 (0%) 
  Digitalis 6 (6%) 0 (0%)** 11 (73%) 0 (0%) 
   *Information available for 89 subjects 
 **Information available for 8 subjects 
 
 
Fluorometric detection of cathepsin activity (I) 
To detect the total activity of cathepsins S, K, and V in the aortic valves, cryostat sections of 
stenotic and control valves were diluted in 50µl of 20 mM MES buffer (pH 6.0; containing 
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2.5mM EDTA, 150 mM NaCl, 0.035% Brij, and 2.8 mM DTT) on 96-well microtiter plates. 
Enzymatic activity was kinetically measured by detecting the degradation of the synthetic 
substrate Z-Phe-Arg-7-amido-4-methylcoumarin (AMC) by fluorometry. A specific inhibitor of 
cysteine proteases, trans-epoxysuccinyl-L-leucylamido(4-guanidino)butane (E64; 20 µM), was 
used in the inhibition experiments. Human recombinant cathepsins S and V were used as 
positive controls. 
 
 
Table 5. Primary antibodies used in Studies I-IV. 
 
Antigen 
Clone / Cat 
number Host Isotype Conc. Source Study 
Cathepsin S 1E3 / ab11059 Mouse IgG1 1.0 µg/ml Abcam Ltd, Cambridge, UK I 
Cathepsin V AF1080 Goat IgG 1.0 µg/ml R&D Systems, MN, USA I 
CD-31 (EC)* JC70A / M0823 Mouse IgG1k 10.0 µg/ml DAKO, Clostrup, Denmark I-IV 
CD-34 (EC)* QBEnd/10  
/ NCL-L-END 
Mouse IgG1k 0.5 µg/ml Novocastra, Newcastle 
upon Tyne, UK 
I-IV 
CD-36 FA6-152 Mouse IgG1 2.0 µg/ml Beckman Coulter, CA, USA IV 
CD-68 (MØ) PG-M1/M0876 Mouse IgG3 0.4 µg/ml DAKO I, III, IV 
CD-163 (MØ) 5C6-FAT / 
BM4041 
Mouse IgG1 1.0 µg/ml Acris Antibodies, 
Hiddenhausen, Germany 
I, III, IV 
Cystatin C AF1196 Goat IgG 4.0 µg/ml R&D Systems I 
LOX-1 MAB1798 Mouse IgG2b 5-10 µg/ml R&D Systems, MN, USA IV 
LYVE-1 AF2089 Goat IgG 1.0 µg/ml R&D Systems III 
MCSP (aka 
NG2, P) 
LHM2 / ab20156 Mouse IgG1k 2.4 µg/ml Abcam plc, Cambridge, UK II 
Osteocalcin 
(O) 
MAB1419 Mouse IgG1 2.0 µg/ml R&D Systems II 
S-100 Z0311 Rabbit   9.0 µg/ml DAKO I 
SMC Actin 
(MFB) 
1A4 / M0851 Mouse IgG2a 1.4 µg/ml DAKO II-IV 
SR-A1 MAB27081 Mouse IgG1 1.0 µg/ml R&D Systems IV 
SR-B1 ab369 Rabbit   5 µg/ml Abcam IV 
Tryptase (MC) AA1 / M7052 Mouse IgG1k 2.4 µg/ml DAKO II-IV 
Tryptase (MC)   Rabbit   0.6 µg/ml A kind gift from I. 
Harvima, Kuopio, Finland 
II, IV 
VEGF A-20 / sc-152 Rabbit   4.0 µg/ml Santa Cruz Biotechnology, 
CA, USA 
II 
VEGF-C AF752 Goat IgG 5.0 µg/ml R&D Systems III 
VEGF-D AF286 Goat IgG 10.0 µg/ml R&D Systems III 
VEGF-R3 AF349 Goat IgG 6.7 µg/ml R&D Systems III 
Vimentin 
(MFB) 
VIM 3B4  
/ NCL-VIM 
Mouse IgG2a 0.13 µg/ml Novocastra II, III 
EC = endothelial cells, MØ = Macrophages, P = Pericytes, O = Osteoblasts, MFB = Myofibroblasts,  
MC = Mast cells 
*Used as a mixture in order to detect neovessels (Jeziorska and Woolley 1999) 
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Histological, immunohistochemical, and double immunofluorescence stainings (I-IV) 
Cryostat sections of snap-frozen aortic valve leaflets were used for histological and 
immunohistochemical analyses in Studies I-IV. Myofibroblasts were cultured on coverslips and 
fixed with paraformaldehyde for the immunohistochemical stainings in Study II. In the 
histological staining used to detect elastin degradation in Study I, elastin fibers were stained 
dark purple with a hematoxyline-iodine-ferric chloride solution. Excess staining was then 
differentiated with a dilute ferric chloride solution, and the samples were counterstained with 
van Gieson solution to visualize collagen fibers (Accustain Elastic stain kit, Sigma-Aldrich). 
 
Immunohistochemical stainings were performed with standard avidin-biotin complex (ABC) (I-
III) and horseradish peroxidase (HRP) (IV) techniques using commercial kits according to the 
manufacturers’ instructions (Vectastain Elite ABC kit, Vector laboratories; Dako Envision 
system-HRP, Dako) with minor modifications. All the primary antibodies used in Studies I-IV are 
presented in table 5. Cathepsin S signal was amplified with a commercial tyramide signal 
amplification (TSA) Kit (#22, Molecular probes). In order to detect possible colocalization of the 
studied antigens with valvular cell types, primary antibodies were used as mixtures and 
detected with isotype-specific Alexa Fluor® secondary antibodies (Invitrogen). In all the 
stainings, host and isotype-specific nonimmune immunoglobulins were used as negative 
controls. 
 
The stainings were analyzed using light or epifluorescent microscopy, and the subcellular 
distribution of tryptase and VEGF-A in mast cells (II) was also visualized with confocal 
microscopy. The sample area, the size of calcific nodules, and valvular elastin and 
myofibroblast contents were calculated with computer-assisted morphometry using SPOT 
Advanced software. The grade of valvular calcification was determined by assessing the 
number of minor (cross section <5 mm
2
) and major (cross section >5 mm
2
) calcific nodules as 
follows: 1 = none; 2 = one minor; 3 = several minor; 4 = one or more minor and major, or 
several major nodules. 
 
Human aortic valve myofibroblast cell culture (II-IV) 
Myofibroblasts were isolated from human aortic valves freshly obtained at valve replacement 
surgery due to AVS or AVR (Table 5) using a previously described outgrowth method (Helske et 
al. 2007). The myofibroblast phenotype was confirmed with immunohistochemical stainings 
against α-actin and vimentin (II, Supplemental Figure II). To investigate the effect of various 
stimuli on the myofibroblasts, the cells were incubated in serum-free culture media with or 
without the studied substances for 24 and/or 48 hours at 37 °C. All experiments were 
performed with subconfluent myofibroblasts at passages four to five and in triplicates with 
cells from multiple donors. The secretion of VEGF-A and inflammatory cytokines into the cell 
culture media was detected with commercial enzyme-linked immunoassays (ELISA) according 
to instructions provided by the manufacturer (R&D Systems). Changes in cellular messenger 
RNA (mRNA) expression were detected from cell lysates with PCR methods as described below. 
 
In order to investigate the possible effects of cigarette smoke on the myofibroblasts, cigarette 
smoke-treated culture medium was prepared as follows. A burning cigarette was connected to 
a sterile 50 ml syringe with plastic tubing.  Cigarette smoke was suctioned into the syringe 
containing 10 ml of serum-free culture medium with vigorous mixing between cycles. The 
medium containing the water-soluble components of cigarette smoke was then diluted and 
used in culture experiments. 
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Table 5. The number and origin of aortic valves used in cell culture experiments. A total of 22 
stenotic and 5 control valves were used in Studies II-IV. 
 
Study Aortic valve stenosis Aortic valve regurgitation 
II 7 2 
III 11 0 
IV 12 4 
 
 
Polymerase chain reaction (PCR), competitive PCR, and quantitative PCR (I-IV) 
Conventional (Cathepsins S and K, and cystatin C), semi-quantitative competitive (VEGF-A), and 
quantitative (Cathepsin V, VEGF-A, VEGF-C, VEGF-D, VEGFR-2, VEGFR-3, SR-A1, SR-B1, CD36, 
and LOX-1) PCR were performed using standard PCR methods further described in the original 
publications. The used primers and probes are also described in the original articles. In 
conventional and competitive PCR, the PCR products were quantified with a Gel Doc 2000 gel 
documentation system (Bio-Rad), and in competitive PCR the competitor-to-target ratio was 
plotted against the logarithm of the competitor DNA molecules. In the qPCR analyses, the data 
were normalized to an endogenous control, glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), and relative units were calculated with a comparative Ct method using the formula  
2
-∆∆C
T (Livak and Schmittgen 2001). 
 
LAD2 and human mast cell culture (II-IV) 
Human LAD2 mast cells, described in (Kirshenbaum et al. 2003), were only used to generate 
mast cell-conditioned medium (referred to as releasate in the text) in Study II. To prepare the 
releasate, the LAD2 cells were stimulated with calcium ionophore, and the media containing 
mast cell-derived substances was collected after a 24-hour incubation at 37 °C. All other 
experiments on mast cells were performed with human peripheral blood-derived mast cells 
generated and activated according to Lappalainen and coworkers (Lappalainen J. et al. 2007). 
In order to study the effect of myofibroblasts on the VEGF-A production by the mast cells, the 
mast cells were stimulated with serum-free myofibroblast-conditioned medium collected from 
valvular myofibroblast cell culture after a 24-hour incubation at 37 °C. VEGF-A secretion into 
the mast cell culture media was detected with a commercial ELISA kit (R&D Systems). 
 
Endostatin and VEGF-C degradation experiments (II-III) 
So as to study the effect of mast cell tryptase on endostatin, human recombinant endostatin 
(ProSpec-Tany TechnoGene Ltd) was incubated with or without human skin beta tryptase 
(Promega) in 50 mM Tris buffer (pH 7.4) for 0 min, 15 min, and 1,3,6, and 24 hours at 37 °C. 
Protein fragmentation was detected by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and by analyzing the gels with GelDoc 200 (Bio-Rad) after Simply 
blue staining (Invitrogen). To investigate the effects of mast cells on VEGF-A and VEGF-C 
secreted by valvular myofibroblasts, myofibroblast-conditioned media was incubated with or 
without mast cell releasate (prepared as above). The effect of specific proteases was tested by 
incubating recombinant human VEGF-C (R&D Systems) with or without mast cell releasate, 
human skin beta tryptase (Promega), recombinant human cathepsin G (Calbiochem), or 
recombinant human chymase (Sigma-Aldrich) for 24 hours at 37 °C. VEGF-A and VEGF-C were 
quantified with commercial ELISA kits (R&D Systems) 
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Isolation and oxidation of low-density lipoprotein (LDL) (IV) 
Human LDL was isolated from the plasma of healthy volunteers (Finnish Red Cross) by 
sequential ultracentrifugation as described by Havel and coworkers (Havel et al. 1955), and 
protein concentrations were measured according to the Lowry method (Lowry et al. 1951).  For 
oxidation, the lipoproteins were dialyzed overnight at +4 °C against phosphate-buffered saline 
(PBS) and incubated in the presence of 10 µM CuSO4 for 18 hours at 37 °C. LDL oxidation was 
verified with Cellulose Acetate Electrophoresis (CAE) of Lipoproteins, and the degree of 
oxidation was determined by measuring thiobarbituric acid-reactive substances (TBARS). 
Sterile-filtered oxLDL was then used in cell culture experiments. 
 
Statistical analyses (I-IV) 
Normality of distributions was tested with the Kolmogorov-Smirnov method. In group 
comparisons, Student’s T-test was used for normally distributed data, and the nonparametric 
Mann-Whitney U test for skewed data and also for a small number of cases (n≤10/group). 
Respectively, Pearson’s product-moment or Spearman’s rank correlation coefficients were 
calculated for correlations. Statistical significance was set at p≤0.05. The current versions of 
SPSS for Windows software were used in all statistical analyses. 
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V RESULTS AND DISCUSSION 
 
 
 Angiogenesis and lymphangiogenesis in AVS 1.
 
1.1. Morphological classification and localization of valvular neovessels 
and lymphatic vessels (II-III) 
 
First, we characterized valvular neovascularization using immunohistochemical stainings 
against the endothelial cell markers CD31 and CD34, and the pericyte marker NG2. We found 
that blood vessels were present in 80 of the studied 85 stenotic aortic valves (94 %), and in only 
2 of the studied 20 control valves (10%). The density of blood vessels was significantly higher in 
the stenotic valves as compared to the controls (II, Figure 2A). In line with previous reports 
(Charest et al. 2006), neovessels in the stenotic aortic valves localized close to calcific nodules, 
amidst inflammatory cell infiltrates, and close to valvular surface. Some of the typical 
localizations of valvular neovessels are demonstrated in Figure 5 (unpublished results). The 
findings were similar in bicuspid (n=13) and tricuspid (n=65) valves. In the two control valves, 
neovessels were detected primarily at the leaflet base, i.e. close to its aortic interface. 
 
 
 
 
Figure 5. CD31/CD34 stainings of stenotic aortic valves showing cross-sectional neovessels as 
reddish-brown circles. Previously unpublished results. A) Neovessels are abundant in a cell-rich 
area (right), but distinctly absent from an acellular, fibrotic area (left). B) Neovessels localizing 
to CD34-positive progenitor cell islets as described in (Charest et al. 2006). C) Neovessels close 
to calcifying nodules (blue). Scale bars = 100 µm. 
42   │   RESULTS AND DISCUSSION 
_____________________________________________________________________________ 
Cross-sectional neovessels were classified into three categories according to their size: small 
microvessels with one to two endothelial cells forming a small lumen, medium microvessels 
with more than two endothelial cells forming a larger lumen, and mature arterioles with an 
organized, α-actin-positive vessel wall (II, Figure 1, A-C). All three types of blood vessels were 
found in the stenotic aortic valves, and only small microvessels were detectable in the control 
valves. In the NG2 stainings, all arterioles and some of the microvessels were surrounded by 
pericytes (II, Figure 1, D and E).  
 
The presence of lymphatic vessels in advancing AVS was assessed with LYVE-1 and VEGFR-3 
stainings of stenotic, sclerotic, and control aortic valves (III, Figure 1, A-D). Like blood vessels, 
lymphatic vessels typically resided in areas with abundant inflammatory cell infiltration (not 
shown), and the density of lymphatic vessels correlated positively with the density of 
neovessels (III, Figure 1F). In contrast to the high occurrence of valvular blood vessels, cross 
sections of lymphatic vessels were found in only 15 (38%) of the studied 40 stenotic valves, in 
two (40%) of the studied 5 sclerotic valves, and in one (5 %) of the studied 20 control valves (III, 
Figure 1E). The number of investigated sclerotic valves was small, rendering it infeasible to 
compare lymphatic vessel densities between the sclerotic and the stenotic aortic valve 
samples. Nevertheless, the highest lymphatic vessel densities were observed in the stenotic 
valves (III, Figure 1E). Importantly, the finding that even early sclerotic valves contained several 
lymphatic vessels suggests that, besides angiogenesis, lymphangiogenesis represents an early 
phenomenon in the pathogenesis of AVS. The one control sample staining positive for 
lymphatic vessels contained two cross sections of lymphatic vessels and also presented with 
the highest density of blood vessels (8 cross sections of blood vessels, data not shown). 
 
There were noticeably fewer lymphatic vessels than blood vessels in the stenotic valves (Figure 
6A): In the 15 valve samples containing lymphatic vessels, the average proportion of lymphatic 
vessels compared to the number of blood vessels was 5 % (calculated from data in Figure 6A). 
Similar relative rarity of lymphatic vessels as compared to blood vessels has also been observed 
in atherosclerotic plaques (Nakano et al. 2005), specific percentages being incomparable due to 
differences in the methodological assessment. 
 
Most blood vessels observed in the stenotic aortic valves were small or medium-sized 
microvessels, while arterioles were more sparse (Figure 6B). The proportion of vascular 
pericyte coverage was not specifically assessed in Study II, but pericytes mostly colocalized with 
organized blood vessels, and the vast majority of valvular microvessels were pericyte-negative. 
Interestingly, pericytes integrate with vascular endothelial cells during blood vessel maturation, 
and decreased pericyte coverage is thought to correlate with vascular instability and 
endothelial cell proliferation (Allt and Lawrenson 2001, Yancopoulos et al. 2000). Thus, 
immature microvessels lacking pericytes are more susceptible to angiogenic sprouting. In 
addition to providing structural support, pericytes may also modulate microvessel permeability 
(Allt and Lawrenson 2001). Whether the pericytes covering valvular blood vessels act in favor 
of vascular permeability or stability remains unclear. Either way, the possible stabilizing effects 
of valvular pericytes fail to hinder the observed angiogenic response and the infiltration of 
inflammatory cells and lipids into the stenotic valves. 
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Figure 6 (Redrawn from data presented in II, Figure 3; and in III, Figure 1E). 
A) The numbers of blood vessels and lymphatic vessels in the same subpopulation of 40 
stenotic aortic valves. Neovessels were present in two and lymphatic vessels in one out of the 
20 control samples (not shown). Individual data points are shown, lines indicate medians.  
B) The average numbers of different types of blood vessels found in the studied 85 stenotic 
aortic valves (classification: II, Figure 1, A-C). Data are presented as mean + SD. 
 
 
1.2. Associations of valvular neovessels and lymphatic vessels with 
inflammation and calcification (II-III) 
 
1.2.1. Blood vessels, lymphatic vessels, and inflammation 
 
As stated above, neovessels and lymphatic vessels in the stenotic aortic valves typically 
localized in areas abundant with inflammatory cells. Moreover, we found that the density of 
valvular blood vessels correlated positively with the density of mast cells in the same samples 
(II, Figure 2B). The correlation remained significant for all three vessel types individually 
(r=0.29, p=0.007; r=0.39, p<0.001; and r=0.36, p<0.001 for small microvessels, medium 
microvessels, and arterioles, respectively). Furthermore, in double immunofluorescence 
stainings of a subpopulation of 10 stenotic aortic valves, 83% of valvular mast cells resided in 
the close proximity of a neovessel (<50µm) (II, Figure 4, A-C). Similar to previous findings 
(Helske et al. 2004b), almost all the mast cells in the stenotic valves were activated, as 
determined by a degranulated histological appearance. The density of lymphatic vessels also 
correlated positively with valvular mast cell density (III, Figure 1G), which corresponds to the 
evident association between valvular lymphatic vessels and blood vessels described above.  
 
The spatial proximity of valvular mast cells and blood vessels together with the overall 
correlation of valvular mast cells with blood vessels and lymphatic vessels suggests that mast 
cells may influence valvular angiogenesis and lymphangiogenesis. Such close localization of 
mast cells and neovessels has also been observed in abdominal aortic aneurysms (Mäyränpää 
et al. 2009) and in coronary atherosclerotic plaques (Kaartinen et al. 1996a), where mast cells 
secrete the proangiogenic basic fibroblast growth factor (Lappalainen H. et al. 2004). In 
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addition to the secretion of specifically proangiogenic molecules, inflammatory cells may 
promote angiogenesis by increasing vascular permeability and by promoting angiogenic 
processes in ECM remodeling (Arroyo and Iruela-Arispe 2010). Furthermore, activated mast 
cells accumulate subendothelially in coronary artery plaques, in which they potentially 
contribute to endothelial erosion by secreting proteases capable of degrading VE-cadherin and 
fibronectin, both of which are necessary for endothelial cell adhesion (Mäyränpää et al. 2006). 
Overall, mast cells could act in concert with valvular macrophages and other inflammatory cells 
in forming the inflammatory environment that potentially triggers and sustains valvular 
angiogenesis. 
 
1.2.2. Blood vessels associated with valvular calcification 
 
Valvular blood vessel density also correlated with valvular calcification grade (II, Figure 3), 
which was defined by the presence and extent of cross-sectional calcific nodules. Out of the 
three vessel types, this correlation was evident for the density of medium microvessels and 
arterioles, but not for small microvessels (r=0.29, p=0.007; r=0.37, p<0.001; r=0.26, p=0.02 for 
medium microvessels, arterioles, and all neovessels, respectively). Importantly, as the 
strongest correlation was found with mature arterioles, advanced angiogenic remodeling 
seems to parallel other histological hallmarks of AVS. As the small microvessels, in turn, are 
likely to be the most newly formed vessels, their equal presence at all stages of valvular 
calcification would indicate active angiogenesis even at a histologically advanced stage of the 
disease. Moreover, in group comparisons, the densities of all types of blood vessels were 
higher in the most severe calcification group as compared to moderately calcified valves. 
 
In contrast to our findings, the highest density of blood vessels has previously been reported in 
moderately calcified valves and hemodynamically moderate stenosis rather than at the end-
stage of the disease (Charest et al. 2006, Soini et al. 2003). In these investigations, neovessels 
were detected with stainings against von Willebrand factor (vWF) and Factor VIII, which occur 
as a complex in endothelial cells. In our studies, we used a combination of CD31 and CD34 
antibodies, which has been shown to be significantly more effective than targeting vWF in 
detecting small microcapillaries in atherosclerotic plaques (Jeziorska and Woolley 1999). 
Considering that 46 % of all the blood vessels in Study II were such small microvessels 
(calculated from data in Figure 6B), the chosen antibodies form a major source of error in the 
past investigations.  
 
In addition, we used unprocessed frozen tissue, whereas other studies assessing valvular blood 
vessel density have used paraffin-embedded (Soini et al. 2001) or partially decalcified (Charest 
et al. 2006) tissue material. In unprocessed frozen tissue, calcified areas often disintegrate 
upon cryostat sectioning, whereas e.g. paraffin-embedding facilitates the sectioning of such 
calcified tissue, providing better morphology at the cost of losing some antigen reactivity.  To 
avoid methodological bias from the altered morphology in our cryostat sections, we calculated 
the section area from the remaining connective tissue. Thus, massive calcification of severely 
stenotic samples was excluded in our calculations, resulting in relatively higher vessel densities 
in the stenotic valves as compared to the previous investigations. The average number of at 
least larger vessels has likely been similar in all the studies. This would also explain why we 
found a positive correlation with valvular calcification grade, while the previous results have 
shown the opposite (Charest et al. 2006) or being insignificant (Soini et al. 2003), possibly due 
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to the increase in cross-sectional area in the density equations in valves with massive calcific 
nodules.  
 
Considering these methodological differences, a feasible conclusion from our findings would be 
that noncalcified areas of otherwise heavily calcified valves have higher vessel densities than 
those of less calcified valves. Furthermore, the observed decrease in vascular densities in some 
studies seems to result from an increase in the calcific masses as the stenosis progresses rather 
than from an actual decrease in valvular blood vessel content. Thus, angiogenic activity may 
contribute to the histological progression of AVS even at the end-stage of the disease. 
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 Local regulation of valvular angiogenesis and 2.
lymphangiogenesis 
 
2.1. Extracellular matrix remodeling – cathepsins S, K, and V, and their 
inhibitor cystatin C in AVS (I) 
 
Disruption of normal valvular connective tissue structure is involved in the development of AVS 
(Otto et al. 1994). In addition, a number of proteolytic enzymes, including matrix metallo-
proteinases and mast cell-derived tryptase, chymase, and cathepsin G, have been implicated in 
the pathological ECM remodeling that leads to thickening and stiffening of the stenotic valves 
(Edep et al. 2000, Helske et al. 2004b, Helske et al. 2006). These proteases may also be involved 
in valvular angiogenesis, as summarized in the Introduction, Table 1. In Study I, we aimed at 
identifying additional ECM-degrading proteases, cathepsins S, K, and V, in the aortic valves and 
at clarifying their role in AVS and valvular angiogenesis. We also assessed their endogenous 
tissue inhibitor cystatin C, the downregulation of which has been implicated in the pathological 
ECM remodeling of atherosclerotic plaques (Shi et al. 1999). The results of Study I are 
summarized in Table 6. 
 
Measuring total cathepsin activity from cryostat sections of 7 stenotic and 7 control valves 
using a fluorogenic substrate revealed the presence of enzymatically active cathepsins in the 
aortic valves. Furthermore, total cathepsin activity was significantly higher in the stenotic 
valves as compared to the controls (I, Figure 6B). In order to investigate the selected cathepsins 
individually, the mRNA expression of cathepsins S and K, along with cystatin C were studied 
from 32 stenotic and 13 control valves with semi-quantitative PCR, and the mRNA expression 
of cathepsin V was quantified with qPCR (Table 6). No differences were observed between the 
mRNA levels in bicuspid and tricuspid aortic valves.  
 
To find out which cells were responsible for the increased cathepsin and cystatin C production 
in the stenotic valves, we performed a series of immunohistochemical and double 
immunofluorescence stainings against macrophage, myofibroblast, endothelial cell, and 
chondrocyte markers (see Methods, Table 5). Due to the lack of a reliable primary antibody, we 
were unable to investigate the cellular expression profile of cathepsin K. The expression 
patterns of the cathepsins and cystatin C in AVS are summarized in Table 6. Cathepsins S and V 
were present in the valvular surface endothelium of both stenotic and control valves. 
Remarkably, cathepsin V was also produced by neovascular endothelial cells of the stenotic 
valves and was present in some surrounding pericytes.  As the staining of cathepsins S and V, 
cystatin C-positive staining was also more abundant in the stenotic valves. Importantly, cystatin 
C was absent from vascular endothelial cells of neovessels in the stenotic valves.  
 
Cystatin C also colocalized with preserved elastin fibers in the stenotic valves, suggesting a role 
for cystatin C in maintaining valvular elasticity. This was further investigated by incubating 
cryostat sections of healthy aortic valve leaflets with recombinant human cathepsins S, K, and 
V in the absence or presence of cystatin C. The sections were then stained for elastin and 
collagen, and analyzed by computer-assisted morphometry. The average elastin content after a 
24-hour incubation with control buffer was 45 ± 16 %. Incubation with the cathepsins resulted 
in statistically significant decreases of the valvular elastin content to 25 ± 12 % for cathepsin S, 
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33 ± 13 % for cathepsin K, and 34 ± 13 % for cathepsin V (I, Figure 6A). Cystatin C was, indeed, 
able to counteract the elastolytic effects of all three cathepsins (I, Supplemental Figure III). 
 
 
Table 6. The expression of cathepsins S, K, and V, and cystatin C in AVS (I). Detailed descriptions 
and corresponding references are provided in the text. 
 
 
Substrates Particular actions 
mRNA 
expression 
in AVS  
(I, Figure 1) 
Staining profile in the 
aortic valves 
(I, Figures 2-4) 
Cathepsin S 
Multiple ECM 
components 
ECM degradation in 
capillary sprouting, 
AVS progression 
Increased 
Increased in AVS; Some 
macrophages, 
chondroblast-like cells, 
endothelial cells lining 
valvular surface 
Cathepsin K Elastin, collagen I Bone remodeling Increased - 
Cathepsin V 
Elastin, 
Plasminogen 
ECM degradation, 
anti-angiogenic? 
Increased 
Increased in AVS; 
Endothelial cells lining 
valvular surface and 
neovessels, some 
pericytes 
Cystatin C 
Cathepsin 
inhibitor 
Counteracting the 
cathepsins 
Increased 
Increased in AVS; 
Macrophages, 
endothelial cells lining 
valvular surface, 
chondroblast-like cells 
 
 
Altogether, the results from Study I show that cathepsin activity is increased in stenotic aortic 
valves, and that the local valvular production of cathepsins S, K, and V, as well as their inhibitor 
cystatin C, is induced in AVS. Moreover, their localization suggests that they have distinct roles 
in valvular ECM degradation, bone remodeling, and angiogenesis. Remarkably, only cathepsin V 
was expressed in the endothelial cells of valvular neovessels, while its inhibitor, cystatin C, was 
absent from these cells. Cathepsin V possesses potent elastolytic properties (Yasuda et al. 
2004), which could contribute to matrix degradation required for angiogenic sprouting. In 
contrast to this potentially angiogenic feature, cathepsin V has been proposed to have an 
inhibitory effect on corneal angiogenesis by generating angiostatin-like molecules from 
plasminogen (Puzer et al. 2008). Confusingly, this action would also provide an indirect 
angiogenic function for cystatin C, which has traditionally been considered a protective factor 
in atherosclerotic diseases. Although the presence of angiostatin in aortic valves is currently 
unknown, the neovascular localization of cathepsin V suggests that it may possess a function, 
that for the time being remains unfocused, in the regulation of valvular angiogenesis. 
 
Unlike cathepsin V, cathepsin S has a clearly established role in angiogenesis. Cathepsin S 
seems to be crucial for the formation of neovessels even in atherosclerotic plaques (Liu J. et al. 
2004). Subsequent investigations have confirmed the pathological nature of cathepsin S in AVS 
by revealing that its actions may actually be crucial for valvular calcification. In a mouse model 
of AVS, cathepsin S deficiency led to a significant decrease in elastin degradation, and reduced 
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calcification in the valve leaflets (Aikawa et al. 2009). Interestingly, serum levels of cystatin C 
were significantly lower in the mice lacking cathepsin S than in the control group (Aikawa et al. 
2009), parallel to our findings which state that cathepsin S and cystatin C expressions were 
simultaneously increased. These results are inconsistent with findings in atherosclerotic 
lesions, where cystatin C is, in fact, downregulated (Shi et al. 1999). Neovascularized areas of 
the plaques, however, contain more cystatin C than the surrounding lesion (Shi et al. 1999), 
possibly in effort to control pathological angiogenesis. In fact, the observed parallel 
overexpression of the cathepsins and cystatin C, as well as their multiple functions, complicate 
the interpretation of their net effect in the aortic valve.  
 
Our observation on cathepsin S being present in the chondroblast-like cells in calcifying human 
valve tissue suggests that the role of cathepsin S in valvular calcification reported by Aikawa 
and coworkers could extend to humans as well (Aikawa et al. 2007). Cathepsin K being 
predominantly expressed by osteoclasts (Brömme et al. 1996), increased valvular cathepsin K 
expression could also contribute to bone formation in the stenotic valves. In atherosclerotic 
plaques, cathepsin K participates in plaque development and remodeling, and disruption of the 
cathepsin K gene slows down the progression of atherosclerosis and promotes plaque fibrosis 
in an animal model (Lutgens et al. 2006).  Cathepsin K is also present in atherosclerotic plaques 
of human coronary arteries, where it may serve macrophage foam cells in degrading plaque 
ECM components (Barascuk et al. 2010). Controversially, cathepsin K downregulation in the 
mouse model augmented scavenger receptor-mediated uptake of lipids by macrophages, 
increased CD36 expression being particularly implicated in this process (Lutgens et al. 2006). 
Interestingly we found CD36 mRNA expression to be decreased in AVS in Study IV (see Section 
2.3.1. below). As cathepsin K mRNA expression, in turn, was increased in AVS, a regulatory 
connection between CD36 and cathepsin K, as proposed by Lutgens and coworkers, could also 
be operative in the aortic valves. Unfortunately, the immunohistochemical staining of 
cathepsin K in our study of AVS (I) was unsuccessful, leaving several unanswered questions 
regarding the stature of cathepsin K in this disease. Therefore, more information on the 
valvular localization of cathepsin K, as well as the functional role of cathepsin V, is needed to 
demonstrate their relevance in the pathogenesis of AVS. 
 
 
2.2. Valvular expression of VEGF-A, VEGF-C, VEGF-D, and their receptors 
VEGFR-2 and VEGFR-3 (II-III) 
 
2.2.1. Local production 
 
Angiotensin II, which is capable of inducing VEGF-A expression (Williams et al. 1995), is present 
and locally produced in stenotic aortic valves (Helske et al. 2004b, O'Brien et al. 2002). Both 
VEGF-A and VEGFR-2 have been previously reported in stenotic aortic valves, VEGF-A having 
been detected only in valvular endothelial cells and myofibroblasts (Soini et al. 2003). In studies 
II and III, VEGF-A, VEGF-C, VEGF-D, and VEGFR-3 were detected from the aortic valves using 
immunohistochemistry. VEGF-C, VEGF-D, VEGFR-2, and VEGFR-3 were also studied with qPCR 
(III, 10 stenotic and 10 control valves). The expression profiles of the studied VEGFs and VEGFRs 
in aortic valve tissue are summarized in Table 7. Detailed descriptions of their properties and 
function along with corresponding references can be found in the Introduction (Section 4.1.2), 
as well as in the discussion below. 
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Table 7. The expression of VEGF-A, VEGF-C, VEGF-D, and their receptors VEGFR-2 and VEGFR-3 
in aortic valve tissue (II and III). 
 
 
Receptor / Function 
Expression in the aortic 
valve (mRNA levels)  
(III, Figure 3) 
Staining profile in the aortic valve 
(II, Figure 4; III, Figures 1-2) 
VEGF-A 
(II) 
VEGFR-1/2 - 
Mast cells, myofibroblasts, 
endothelial cells lining valvular 
surface and neovessels 
VEGF-C 
(III) 
VEGFR-2/3 
High, similar in AVS and 
controls 
Myofibroblasts, endothelial cells 
lining valvular surface and neovessels 
VEGF-D 
(III) 
VEGFR-2/3 Low, increased in AVS 
Myofibroblasts, endothelial cells 
lining valvular surface 
VEGFR-2 
(III) 
Angiogenesis,  
vascular permeability, 
osteogenesis 
High, increased in AVS - 
VEGFR-3 
(III) 
Lymphangiogenesis, 
osteoblast 
differentation? 
Low, increased in AVS 
Lymphatic endothelial cells, 
endothelial cells lining valvular 
surface 
 
 
In Study II, we found that 62% of valvular mast cells stained positive for VEGF-A. The presence 
of VEGF-A-positive extracellular granules was confirmed by confocal microscopy, indicating 
that mast cells in the stenotic aortic valves produce VEGF-A and release it upon activation. 
VEGF-A was also found in the previously described cell types. In the control valves, surface 
endothelium and some subendothelial, resting mast cells were VEGF-A-positive. VEGF-D was 
only patchily detected in the surface endothelium, which concurs with previous work indicating 
endothelial cells as a source of VEGF-D in normal arteries (Rutanen et al. 2003). In the normal 
arteries, VEGF-D was also expressed by smooth muscle cells, whereas in atherosclerotic 
plaques it was expressed mainly by macrophages (Rutanen et al. 2003). In our stainings, 
however, valvular macrophages remained VEGF-C- and VEGF-D-negative (not shown). 
Furthermore, mast cells have been shown to express VEGF-C in mouse tumors (Brideau et al. 
2007). Thus, they were considered a potential source of VEGF-C in our study as well, but 
remained negative for both VEGF-C and -D in the immunohistochemical stainings (not shown). 
VEGF-C and VEGF-D were not double-stained with lymphatic vessels due to overlapping 
primary antibody immunoglobulin classes. Because CD34 may also be expressed by lymphatic 
endothelial cells (Cueni and Detmar 2006), it is conceivable, that some of the observed positive 
staining of VEGF-C in the neovascular sprouts actually localized to lymphatic vessel 
endothelium. 
 
Interestingly, VEGFR-2 mRNA levels were significantly higher in patients with a history of 
smoking, and correlated positively with the peak pressure gradient at echocardiography 
(r=0.744). Although the sample size was small, it is tempting to hypothesize that the soluble 
components of cigarette smoke may promote valvular neovascularization by affecting local 
VEGFR-2 expression. In fact, in the series of experiments on valvular myofibroblasts performed 
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in Study III (presented in III, Figure 4D, discussed in Section 2.2.2), stimulation of the 
myofibroblasts with cigarette smoke also resulted in an increase in VEGFR-2 expression by 
these cells (Figure 7, unpublished data).  
 
 
 
Figure 7. The VEGFR-2 mRNA 
expression of cultured human 
aortic valve myofibroblasts in 
response to cigarette smoke in 
the same three independent 
experiments presented in III, 
Figure 4D.  
 
Previously unpublished data, 
presented as medians and 
interquartile ranges. 
 
 
The identification of mast cells as a novel valvular source of VEGF-A is in line with previous 
work demonstrating VEGF-A production by mast cells (Grützkau et al. 1998). Furthermore, the 
observed release of VEGF-A-containing granules close to valvular neovessels suggests a 
substantial role for these cells in valvular angiogenesis. The increase in valvular VEGFR-2 mRNA 
levels, in turn, is likely to portray the angiogenic activation of valvular endothelial cells, which 
have been shown to express VEGFR-2 (Soini et al. 2003). VEGFR-2 has also been 
immunohistochemically detected in valvular myofibroblasts both in valve tissue and in cultured 
cells (Chalajour et al. 2007, Soini et al. 2003). The investigation by Chalajour and coworkers 
derived from their earlier demonstration of an ex vivo 3D collagen model of capillary tube 
formation by valvular endothelial cells (Chalajour et al. 2004). In this earlier investigation, 
however, only morphological evidence of endothelial outgrowth was presented without 
immunohistochemical confirmation. In subsequent work, the same group found that most of 
the migrated cells were, in fact, α-actin-positive, indicating a myofibroblast rather than an 
endothelial cell phenotype (Chalajour et al. 2007). In addition to VEGFR-2, the myofibroblasts 
also stained positive for the angiopoietin receptor Tie-2 and formed capillary sprout-like 
structures (Chalajour et al. 2007). The specific consequences of VEGFR-2 and Tie-2 activation in 
valvular myofibroblasts, however, remain to be determined. 
 
The observed VEGFR-3-positive vascular structures were also LYVE-1-positive, denoting 
lymphatic endothelium. Interestingly, VEGFR-3 was also expressed by some of the endothelial 
cells lining the valve surface. As VEGFR-3 is expressed by tip cells of angiogenic sprouts (Lohela 
et al. 2009), VEGFR-3-positivity of surface endothelial cells could indicate angiogenic activation 
of these cells. In fact, based on the findings that neovascular clusters concentrate close to 
valvular surface and on the morphological observation that some sprouts seem to originate 
directly from the valve surface, it has been suggested that some of the valvular neovessels may 
form by budding from valvular surface endothelium (Steiner et al. 2010). We also observed 
areas of endothelial migration from the valve surface into the tissue in our immuno-
histochemical stainings (Figure 8, unpublished). Such vascular sprouting could account for 
some of the observed VEGFR-3 upregulation in AVS.  
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Figure 8. CD31/CD34 staining of the surface endothelium of a stenotic aortic valve 
(unpublished). Some of the endothelial cells staining brownish-red in the valve tissue seem to 
directly connect with the valvular surface, supporting the hypothesis that endothelial sprouts 
may originate from the endothelium lining the valvular surface. Scale bar = 100µm. 
 
 
In addition to promoting lymphangiogenesis, the activation of VEGFR-3 by VEGF-D has been 
shown to induce osteoblastic differentiation in mice (Orlandini et al. 2006). The expression of 
VEGFR-3 mRNA, however, was extremely low at least in our experiments with cultured valvular 
myofibroblasts (data not shown), which are a potential source of osteoblastic cells in stenotic 
aortic valves (Liu A. C. et al. 2007). Nevertheless, the increased VEGF-D expression in AVS could 
contribute to the pathological osteogenic environment of the diseased valves.  
 
Although VEGF-C mRNA expression remained unchanged in AVS, the abundance of VEGF-C 
mRNA as compared to that of VEGF-D, as well as the upregulation of VEGFR-2 and VEGFR-3, 
supports the potential role of VEGF-C in valvular lymphangiogenesis. Furthermore, as the 
receptor-binding properties of both VEGF-C and VEGF-D may be posttranslationally modified 
(Achen et al. 1998, Joukov et al. 1997), the correlation between their mRNA expression and 
physiological function may not be linear. Unlike in the expression of VEGF-C, there was a 
significant increase in the valvular mRNA expression of VEGF-D in AVS. As discussed previously, 
VEGF-D may, in addition to being lymphangiogenic, also exert angiogenic effects. Because 
angiogenesis is overrepresented as compared to lymphangiogenesis in the stenotic valves, it is 
conceivable that VEGF-D exerts mostly angiogenic effects in these valves. On the other hand, if 
the main effects of VEGF-D in the valves are lymphangiogenic, these actions are evidently 
insufficient to induce valvular lymphangiogenesis in proportion to angiogenesis.  
 
2.2.2. The role of valvular myofibroblasts 
 
Studies on cultured valvular myofibroblasts 
Since VEGF-A and VEGF-C were detectable in part of the myofibroblasts in stenotic aortic 
valves, we wanted to further explore the production of these growth factors by cultured 
human myofibroblasts derived from stenotic aortic valves. Both growth factors were 
constitutively secreted into the cell culture media by the myofibroblasts. We also explored the 
possibility of the myofibroblasts producing VEGF-D, but it remained undetectable in the cell 
culture media (data not shown). Next, to study the local conditions potentially regulating the 
production of VEGF-A and VEGF-C in the myofibroblasts, we stimulated these cells with factors 
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implicated in the pathogenesis of AVS. We studied the effects of mast cell-derived 
components, the inflammatory cytokine TNF-α, hypoxic conditions, and osteogenic stress. 
Smoking being a risk factor for AVS (Deutscher et al. 1984), we also investigated the influence 
of soluble components of cigarette smoke on the myofibroblasts. Importantly, cigarette smoke 
has previously been shown to activate mast cells, and it has been linked to the pathological 
inflammation and ECM remodeling in AVS (Helske et al. 2008, Helske et al. 2006). The results of 
these experiments are summarized in Table 8. 
 
 
Table 8. The effects of external stimuli on the VEGF-A/C production by valvular myofibroblasts 
derived from stenotic aortic valves. Arrows indicate an increase, decrease, or no response. 
VEGF-A secretion was also studied in control myofibroblasts, the results being similar to those 
observed in myofibroblasts from stenotic valves (not presented). 
 
 
Mast cell 
releasate 
TNF-α Hypoxia 
Cigarette 
smoke 
Osteogenic 
stress 
VEGF-A (II) ↑ ↑ ↑ ↑ ↓ 
VEGF-C (III) ↔/↓* ↑ ↔ ↔/↓** ↔/↓** 
* No effect at mRNA level, protein degradation 
** Only one time point statistically significant 
 
 
Both of the inflammatory stimuli, i.e. the mast cell-derived components and TNF-α, significantly 
induced the VEGF-A secretion of the myofibroblasts (II, Figure 5, A and B).  Furthermore, 
incubating the myofibroblasts in the presence of soluble components of cigarette smoke or in 
hypoxic culture conditions also resulted in increased VEGF-A production (II, Figure 5, C and D). 
The effect of cigarette smoke and TNF-α was similar at the mRNA level (II, Figure 5F). Thus, in 
addition to the association between cigarette smoke and increased VEGFR-2 described above, 
smoking could contribute to the harmful angiogenic response in stenotic aortic valves by 
inducing VEGF-A production. These findings provide a possible mechanism for this known risk 
factor of AVS in the pathogenesis of the disease. Finally, introducing the myofibroblasts to 
osteogenic stress decreased the amount of secreted VEGF-A (II, Figure 5E), a phenomenon also 
occurring during early osteogenic differentiation (Mayer et al. 2005). The VEGF-A production by 
valvular myofibroblasts in response to the above stimuli was similar between cells derived from 
stenotic and non-stenotic aortic valves, the latter ones being obtained at valve replacement 
surgery due to aortic regurgitation (II, Supplemental Figure III). 
 
In addition to VEGF-A, TNF-α also stimulated the VEGF-C expression of valvular myofibroblasts, 
both at protein level and at mRNA level (III, Figures 4B and 5B). Hypoxic culture conditions, in 
turn, showed no effect on the VEGF-C secretion of the myofibroblasts (III, Figure 4C). These 
findings are concurrent with previous work on human fibroblasts demonstrating that hypoxia 
significantly induces the expression of VEGF-A, but not VEGF-B or VEGF-C (Enholm et al. 1997). 
TNF-α was also a plausible inducer of VEGF-C expression based on literature, having been 
shown to increase VEGF-C production in human fibroblasts (Ristimaki et al. 1998). In contrast 
to VEGF-A, cigarette smoke had a minor decreasing effect on VEGF-C production by the 
myofibroblasts evident only at the 24-hour time point (III, Figure 4D). Finally, the VEGF-C 
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response to osteogenic stress was similar to that of VEGF-A, being significant only at the 48-
hour time point (III, Figure 4E). The effects of hypoxia, cigarette smoke, and osteogenic stress 
at protein level were concurrent with the mRNA findings by qPCR (not shown). 
 
Myofibroblasts and mast cells 
Remarkably, the effect of mast cell-derived components on cellular VEGF-C secretion seemed 
to be opposite to the effect it had on VEGF-A production. In fact, adding mast cell releasate to 
the myofibroblasts derived from stenotic valves resulted in a decrease of detectable VEGF-C in 
the culture media (III, Figure 4A). At the mRNA level, however, the production of VEGF-C 
remained constant (III, Figure 5A). These results raised questions regarding possible VEGF-C 
degradation, addressed below in Section 2.4 (Angiogenic and antilymphangiogenic actions of 
valvular mast cells). We also studied the potential effects of myofibroblast-derived factors on 
the VEGF-A production of cultured human mast cells. The mast cells were first generated from 
circulating progenitors by a previously established protocol (Lappalainen J. et al. 2007). We 
then incubated the mast cells with cell culture medium obtained from cultured myofibroblasts 
derived from stenotic aortic valves. Interestingly, the myofibroblasts had produced substances 
that were able to induce the VEGF-A secretion of cultured human mast cells (II, Figure 5G). The 
effect was more pronounced at the 24-hour time point than at the 1-hour time point, 
suggesting a more sustained state of active VEGF-A production rather than an acute release of 
stored VEGF-A in mast cell degranulation process. The interactions between valvular 
myofibroblasts and mast cells are discussed in Section 2.5 (Interplay between valvular mast 
cells and myofibroblasts). 
 
 
2.3. Oxidized LDL and scavenger receptors (IV) 
 
2.3.1. Local expression of scavenger receptors SR-A1, SR-B1, CD36, and 
LOX-1 
 
The presence of oxLDL and its increased deposition in stenotic aortic valves have been reported 
previously (Olsson et al. 1999), but its potential actions in the aortic valves have remained 
unclear, and the presence of oxLDL-binding scavenger receptors in aortic valves has not been 
previously reported. The properties of the studied scavenger receptors, as well as the results 
from all the following analyses, are summarized in Table 9. First, we examined the expression 
of scavenger receptors SR-A1, CD36, and LOX-1, and the atheroprotective SR-B1 in 10 stenotic 
valves and 11 control valves with qPCR. Notably, the relatively highest expression was observed 
in the mRNA levels of SR-A1. We then analyzed the potential expression of these scavenger 
receptors in cultured valvular myofibroblasts derived from both stenotic and control valves 
(n=4 in each group). Based on previous findings reporting that inflammatory cytokines may 
induce the expression of several scavenger receptors (Stephen et al. 2010), we tested the 
effect of two selected inflammatory agents, mast cell releasate and TNF-α, on the cultured 
valvular myofibroblasts. Both the mast cell releasate and TNF-α were able to induce LOX-1 
expression in the myofibroblasts. 
 
In order to examine which cells may be responsible for the observed changes in valvular 
scavenger receptor expression in AVS, we conducted immunohistochemical and double 
immunofluorescence stainings of both stenotic (n=24) and control (n=7) aortic valves (Table 9). 
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By performing these stainings, we also wanted to address the apparent discrepancies in SR-A1 
and CD36 expression between valvular tissue and cultured aortic valve myofibroblasts. In the 
qPCR analyses, SR-A1 mRNA expression was increased in stenotic valve tissue but not in the 
myofibroblasts derived from stenotic aortic valves as compared to controls. In the 
immunohistochemical stainings, SR-A1 was more abundant in the stenotic valves than in the 
control valves, and localized to macrophages in both stenotic and control valves. Thus, valvular 
macrophages rather than myofibroblasts are likely to account for the observed increase in SR-
A1 mRNA expression in stenotic valve tissue.  
 
 
Table 9. The expression of scavenger receptors (SR) SR-A1, SR-B1, CD36 and LOX-1 in AVS. The 
first five columns are modified from (Stephen et al. 2010). 
 
Class SR 
Examples of 
ligands 
Role in 
atherosclerosis 
Potential 
expression-
altering factors 
in AVS 
Expression in 
the aortic valve 
(mRNA levels) 
(IV, Figure 1-2) 
Staining profile 
in the aortic 
valve  
(IV, Figure 3-4) 
A SR-A1 
AcLDL, OxLDL, 
ECM, apoptotic 
cells, activated 
b-cells, bacteria 
OxLDL uptake by 
macrophages 
leading to foam 
cell formation 
Increased by 
oxidative 
stress, OxLDL, 
M-CSF 
Upregulated in 
stenotic valves, 
no change in 
cultured 
myofibroblasts 
in AVS 
Macrophages in 
both control and 
stenotic valves 
B SR-B1 
HDL, LDL, 
OxLDL, 
apoptotic cells 
Reduces 
atherosclerosis 
through reverse 
cholesterol 
transport of HDL 
Decreased by 
OxLDL, TNF-α,  
IL-1, LPS 
Expression 
unchanged in 
AVS 
- 
B CD36 
AcLDL, OxLDL, 
HDL, LDL, VLDL, 
apoptotic cells 
OxLDL uptake by 
macrophages 
leading to foam 
cell formation, 
inhibition of 
angiogenesis* 
Increased by IL-
4, OxLDL*; 
Decreased by 
IL-10, statins* 
Downregulated 
in stenotic 
valves, 
upregulated in 
cultured 
myofibroblasts 
in AVS 
In endothelial 
cells lining the 
valve in both 
control and 
stenotic valves, 
in neovessels of 
stenotic valves, 
in some 
myofibroblasts 
E LOX-1 
OxLDL, ECM, 
apoptotic cells, 
activated 
platelets, 
bacteria 
OxLDL uptake in 
endothelial cells 
leading to 
endothelial 
dysfunction, pro-
angiogenic** 
Increased by 
Ox-LDL, TNF-α, 
shear stress, 
oxidative 
stress, 
endothelin-1, 
angiotensin II 
Upregulated in 
stenotic valves 
and in cultured 
myofibroblasts 
in AVS, mast cell 
releasate and 
TNF-α induce 
expression 
In some 
endothelial cells 
lining the 
stenotic valves 
*(Febbraio and Silverstein 2007) 
**(Jiang et al. 2011) 
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Surprisingly, CD36 was not present in valvular macrophages, but localized to endothelial cells 
lining both valvular surface and neovessels of the stenotic aortic valves. In double 
immunofluorescence stainings, CD36 was also found in some sparse valvular myofibroblasts. In 
the qPCR analyses, CD36 mRNA expression in AVS was decreased in valvular tissue but 
increased in cultured myofibroblasts. The predominant protein expression of CD36 by valvular 
endothelial cells could indeed explain the difference in CD36 mRNA expression between valve 
tissue and cultured myofibroblasts. More specifically, if most of the mRNA expression in the 
qPCR analyses had been derived from valvular endothelial cells, the decrease in their CD36 
expression would have been reflected in the tissue mRNA analyses. Correspondingly, if only 
few valvular myofibroblasts had expressed CD36, their increased CD36 mRNA expression would 
have remained undetected in the tissue analyses. In any case, the possibility remains that the 
changes observed in valvular cells cultured over several passages in vitro do not fully represent 
the in vivo expression profile of these cells in the valvular tissue.  
 
Finally, LOX-1 was immunohistochemically detectable only in the stenotic aortic valves, where 
its expression localized to the valvular surface endothelial cells and the pericytes surrounding 
neovascular endothelial cells. In contrast to the cell culture analyses, LOX-1 expression could 
not be seen in valvular myofibroblasts in the immunohistochemical stainings. As LOX-1 is 
mainly an endothelial receptor, it is conceivable that the lower expression in valvular 
myofibroblasts may have remained below the immunohistochemical detection limit. 
 
Our findings on SR-A1 expression increasing in AVS and localizing to valvular macrophages 
propose a similar role for SR-A1 in AVS than in atherosclerosis, where it significantly 
contributes to macrophage foam cell formation (Stephen et al. 2010). In addition to SR-A1, 
CD36 is also a crucial contributor in atherogenesis, where its inhibitory effects on angiogenesis 
are clearly overcome by its proatherogenic role in macrophage foam cell formation (Febbraio 
and Silverstein 2007). In our analyses, CD36 mainly localized to valvular endothelial cells, 
however, suggesting that it could be a player in the local regulation of valvular angiogenesis in 
addition to its role in foam cell formation. In addition, the expression of this antiangiogenic 
mediator was decreased in AVS, possibly contributing to the local proangiogenic environment.  
 
The expression of LOX-1 was increased in AVS in all the analyses in Study IV. First, the mRNA 
levels of LOX-1 were elevated in the stenotic aortic valves. Second, cultured myofibroblasts 
derived from stenotic valves expressed higher levels of LOX-1 mRNA than those derived from 
control valves. Finally, LOX-1 protein was present in endothelial cells lining the stenotic valves 
but not in those lining the control valves. Notably, its patchy expression may portray 
differences in local blood flow shear stress inducing LOX-1 expression, a mechanism implicated 
in the localized formation of atherosclerotic lesions (Mitra et al. 2011). In line with previous 
findings (Stephen et al. 2010), we found that LOX-1 expression was also induced by TNF-α in 
aortic valve myofibroblasts. Furthermore, we found that mast cell-derived components were 
able to induce LOX-1 mRNA expression in these cells. Our results link LOX-1 to the pathogenesis 
of AVS and indicate that local inflammation could induce its expression in the stenotic aortic 
valves.  
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2.3.2.  A role for oxLDL in valvular inflammation and angiogenesis 
 
The angiogenic potential of small concentrations of oxLDL has been demonstrated in human 
coronary artery endothelial cells, in which oxLDL induces VEGF-A expression and capillary tube 
formation via LOX-1 (Dandapat et al. 2007). Furthermore, oxLDL has been shown to induce the 
expression of a large variety of genes involved in e.g. endothelial cell migration and adhesion 
(Khaidakov et al. 2012). Remarkably, these effects were also counteracted by a LOX-1-blocking 
antibody, suggesting a major role for LOX-1 in all of the angiogenic effects of oxLDL on 
endothelial cells. OxLDL also increases LOX-1 expression (Khaidakov et al. 2012), potentially 
further enhancing the angiogenic effect. Therefore the observed increase in LOX-1 mRNA 
expression in AVS may also result from local deposition of oxLDL in addition to the surrounding 
inflammatory environment as suggested above. More importantly, the eminent role of LOX-1 in 
angiogenesis suggests that its increased expression may be one of the factors behind the 
pathological neovascularization of stenotic aortic valves. The possibility of increased LOX-1-
mediated angiogenesis has also been highlighted in atherosclerosis (Mitra et al. 2011).  
 
Besides its effects on angiogenesis, oxLDL has an established role in the pathological 
inflammation of the arterial wall in atherosclerotic lesions (Tsimikas and Miller 2011). Thus, we 
aimed at further examining the connection between oxLDL and valvular inflammation. For this 
purpose, we stimulated myofibroblasts derived from stenotic aortic valves with 10, 25, or 50 
µg/ml oxLDL, and measured the responses in inflammatory cytokine production from the cell 
culture media by ELISA. Indeed, 25 µg/ml of oxLDL was able to induce the expression of four 
proinflammatory cytokines, MCP-1, IL-6, IL-8, and macrophage colony-stimulating factor (M-
CSF), in the myofibroblasts (IV, Figure 5, A-D). Furthermore, the effect of oxLDL on interleukin 
production increased in a dose-dependent manner (IV, Figure 5, B and D). Considering the 
increased expression of LOX-1 and CD36 in valvular myofibroblasts, these receptors are 
potential contributors to the observed inflammatory response. In addition to the increased 
production of inflammatory cytokines, the activation of scavenger receptors by oxLDL may 
enhance monocyte infiltration and differentiation into foam cell-forming macrophages 
(Stephen et al. 2010), a process implicated in the pathogenesis of AVS as well (Otto et al. 1994). 
Notably, the overall proinflammatory effects of oxLDL may indirectly promote local 
angiogenesis in addition to the more specific mechanisms mediated by LOX-1.  
 
Scavenger receptor activation may also result in a number of other effects potentially involved 
in valvular pathology. Such effects include apoptosis, the expression of adhesion molecule 
genes, increased collagen production, and vascular smooth muscle cell proliferation (Mitra et 
al. 2011, Stephen et al. 2010). Interestingly, LOX-1 is upregulated by angiotensin II (Wang et al. 
2011), which is actively generated and abundantly present in stenotic aortic valves (Helske et 
al. 2004b, O'Brien et al. 2002). Furthermore, oxLDL induces angiotensin type 1 receptor 
expression parallel to LOX-1 expression (Li et al. 2000), suggesting that the previously observed 
upregulation of this angiotensin receptor in stenotic aortic valves (Helske et al. 2004b) may be 
linked to the increase in LOX-1 expression detected in Study IV and may partly derive from the 
actions of oxLDL in the diseased leaflets. Thus, the above novel findings demonstrating 
scavenger receptor expression in the aortic valves could be central to the comprehensive 
understanding of the local pathological mechanisms leading to AVS. 
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2.4. Angiogenic and antilymphangiogenic actions of valvular mast cells   
(II-IV) 
 
Our initial immunohistochemical findings that valvular mast cells produce VEGF-A, but not 
VEGF-C, already indicated an angiogenic but not a lymphangiogenic role for this potent 
inflammatory cell. This impression was further consolidated by experiments on valvular 
myofibroblasts demonstrating that mast cell-derived components induced the expression of 
VEGF-A but not VEGF-C in the myofibroblasts. In fact, the amount of detectable VEGF-C 
decreased as a result of adding mast cell releasate to the myofibroblast culture, suggesting that 
mast cells actually possess antilymphangiogenic potential. As described above, mast cell 
releasate decreased the amount of VEGF-C protein while VEGF-C mRNA expression remained 
constant. We therefore hypothesized that some proteases produced by the mast cells could 
degrade VEGF-C, and acknowledged the possibility of similar effects on VEGF-A. In fact, 
incubating recombinant VEGF-A and VEGF-C proteins with mast cell releasate revealed that 
VEGF-C, but not VEGF-A, was degraded by mast cell-derived components (III, Figure 5C). Next, 
we selected tryptase, chymase, and cathepsin G as potential effector proteases, as all three are 
produced by activated mast cells in stenotic aortic valves (Helske et al. 2004b, Helske et al. 
2006). Notably, all three proteases were also able to degrade intact VEGF-C in vitro (III, Figure 
5D). 
 
We also studied the potential effects of valvular mast cells on endostatin, an antiangiogenic 
molecule detected from stenotic aortic valves (Chalajour et al. 2004). Incubating purified 
human endostatin with recombinant mast cell tryptase indeed resulted in endostatin 
degradation in a time-dependent manner. Proteolytic loss of endostatin was detected by SDS-
PAGE and was visible as a decrease in the intensity of the intact (20 kDa) endostatin band (II, 
Figure 6).  
 
All in all, mast cells in stenotic aortic valves seem to be angiogenic but antilymphangiogenic. 
They produce and secrete the angiogenic VEGF-A but degrade the lymphangiogenic VEGF-C, 
not VEGF-A. Mast cells are also capable of degrading the antiangiogenic endostatin, which 
would further consolidate the role of valvular mast cells as angiogenic effectors. Finally, mast 
cells may indirectly increase the angiogenic effects of oxLDL in the stenotic aortic valves by 
inducing LOX-1 expression in valvular myofibroblasts. Yet another angiogenic action of mast 
cells arises from a recent study in which human mast cells secreted and processed the 
proteoglycan perlecan into fragments containing functional endorepellin, which, in turn, 
regulates angiogenesis and matrix turnover (Jung et al. 2013). Even though the expression of 
perlecan in aortic valves remains obscure, it is obvious that valvular mast cells possess 
intensive angiogenic potential. 
 
The proposed antilymphangiogenic role of mast cells is somewhat shaken by the above-noted 
ability of mast cells to degrade endostatin, because endostatin also has antilymphangiogenic 
effects (Brideau et al. 2007). This would provide the mast cells with indirect lymphangiogenic 
activity as well. Considering that induced angiogenesis is strongly associated with AVS 
(Mazzone et al. 2004, Mohler et al. 2001, Soini et al. 2003), the possible increase in valvular 
endostatin observed by Chalajour and coworkers seems to be insufficient in controlling the 
prominent angiogenic response (Chalajour et al. 2004). Moreover, endostatin overexpression 
has been shown to decrease mast cell infiltration (Brideau et al. 2007), a phenomenon clearly 
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absent from stenotic aortic valves. In fact, the opposite is true: activated mast cells are 
abundantly present in the diseased leaflets, and their number is increased in comparison to 
non-diseased leaflets (Helske et al. 2004b). The increased amounts of valvular mast cells, in 
turn, would significantly contribute to endostatin degradation, thus counteracting the 
production of endostatin. Thus, the net effect of mast cells in stenotic aortic valves would 
conceivably be antilymphangiogenic, even when the prolymphangiogenic effect of endostatin 
degradation by the mast cells is taken into account.  
 
In the VEGF-C degradation experiments, the amount of intact protein was measured with a 
commercial enzyme-linked immunoassay. According to the information provided by the 
manufacturer (R&D Systems, e-mail communication, 2010), this assay should also detect the 
fully processed, angiogenic form of VEGF-C. Nevertheless, a possibility remains that at least 
some mast cell-derived proteases could cleave VEGF-C or other VEGFs into effective, 
modulated forms with distinct receptor-binding patterns. Future investigations on the potential 
capacity of mast cells to generate these modulated VEGFs would certainly elucidate the 
complex role of mast cell proteases on angiogenesis and lymphangiogenesis. 
 
2.5. Interplay between valvular mast cells and myofibroblasts (II-IV) 
 
AVS is characterized both by the abundant accumulation of activated mast cells and by the 
proliferation and activation of valvular myofibroblasts (Helske et al. 2004b, Olsson et al. 
1994b). These cells act together on several pathological valvular processes including the 
sustained inflammatory reaction. Myofibroblasts in the stenotic valves also produce increased 
amounts of collagen (Eriksen et al. 2006), thus contributing to the thickening of the valve 
leaflets. Valvular mast cells, in turn, participate in this adverse remodeling by producing ECM-
degrading proteases, e.g. tryptase, chymase, and cathepsin G (Helske et al. 2004b, Helske et al. 
2006). Mast cell-derived tryptase and chymase also possess profibrotic potential, and 
pharmaceutical inhibition of chymase has been shown to prevent myocardial collagen 
deposition and fibrosis in an experimental animal model (Matsumoto T. et al. 2003, Wygrecka 
et al. 2013). Mast cell-derived cathepsin G, in turn, induces the expression of the profibrotic 
TGF-β1 in human fibroblasts (Helske et al. 2006). Moreover, the colocalization of valvular mast 
cells and TGF- β1 indicates a potential contribution of this mechanism to valvular fibrosis as 
well (Helske et al. 2006). Thus, myofibroblasts and mast cells act in concert in the pathological 
modulation of valvular ECM in stenotic aortic valves. 
 
The joint contributions of mast cells and myofibroblasts extend beyond ECM remodeling. In 
this thesis, we identified several novel mechanisms coordinated by valvular mast cells and 
myofibroblasts that affect angiogenesis and lymphangiogenesis in stenotic aortic valves. First, 
both cell types express VEGF-A in the aortic valve, and both are also able to induce the 
expression of VEGF-A in the other cell type (II). Furthermore, mast cell-derived proteases are 
able to degrade VEGF-C produced by the myofibroblasts (III). Finally, mast cells induce LOX-1 
expression in valvular myofibroblasts (IV), rendering them more susceptible to the effects of 
oxLDL. These mechanisms together with other major findings in this thesis are summarized in 
Figure 9. All in all, the interactions of valvular mast cells and myofibroblasts may promote 
angiogenesis in the aortic valve. In addition, changes in the balance between VEGF-C 
production by the myofibroblasts and its degradation by the mast cells may regulate valvular 
lymphangiogenesis.   
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 General discussion 3.
 
3.1. Angiogenesis and lymphangiogenesis in AVS  
 
3.1.1. Pathological angiogenic switch in AVS 
 
In normal tissue repair, the newly formed capillary network regresses with the resolution of the 
inflammatory stimulus. In the absence of inhibitory signals, however, the positive feedback 
between the inflammatory cells and the immature, leaky vasculature leads to chronic 
inflammation and increased ECM turnover (Arroyo and Iruela-Arispe 2010). This pathological 
angiogenic loop is present in e.g. atherosclerotic lesions (Costa et al. 2007), and many 
histological features indicate that the signals involved in normal vascular regression are also 
impaired in AVS. The presence of organized arterioles in heavily calcified valves implicates that 
these valves have already reached an advanced stage of angiogenic remodeling (II). At the 
same time, both mildly and severely calcified valves contain plenty of newly formed small 
microvessels, indicating active neoangiogenesis (II). Furthermore, the expression of the potent 
angiogenic factor VEGF-A by multiple valvular cells, including mast cells (II), points to a 
proangiogenic switch in the valvular microenvironment. In Study II, we also observed increased 
VEGF-A secretion by valvular myofibroblasts in response to hypoxia. Thus, the increased 
cellularity in stenotic valve tissue and the subsequent increase in local oxygen demand 
comprise one possible mechanism behind the pathological angiogenic activation in AVS. 
Moreover, the extensive connective tissue remodeling in the stenotic aortic valves, including 
the increased expression of cysteine cathepsins (I), enables angiogenic sprouting in the 
presence of abundant VEGF-A (Yancopoulos et al. 2000). 
 
3.1.2. The function of valvular blood vessels and lymphatic vessels 
 
In addition to their response to hypoxia, valvular myofibroblasts may have an angiogenic (II) 
and lymphangiogenic (III) response to the local production of proinflammatory cytokines such 
as TNF-α. Thus, inflammation may be a trigger for angiogenesis and lymphangiogenesis in AVS, 
as it is in other pathological conditions (Arroyo and Iruela-Arispe 2010). Valvular blood vessels 
and lymphatic vessels, in turn, may also affect the course of events leading to chronic, 
sustained inflammation in AVS.  
 
Angiogenesis has a distinct role in chronic inflammation, where it e.g. facilitates inflammatory 
cell infiltration into tissue (Griffioen and Molema 2000). Because valvular neovascular 
endothelial cells express cell adhesion molecules involved in the recruitment of inflammatory 
cells from systemic circulation (Mazzone et al. 2004), neovessels are also likely to facilitate 
inflammatory cell infiltration into the aortic valves, thereby feeding the proinflammatory 
territory of the stenotic leaflets. Lymphatic vessels, in turn, are known to participate in the 
initiation of antigen-specific immune responses involved in e.g. transplant rejection (Cursiefen 
et al. 2004, Kerjaschki et al. 2004). Their role in other types of inflammatory responses is, 
however, less established. In contrast to the pathological role of lymphatic vessels in 
alloimmunization, lymphangiogenesis has been proposed to have an anti-inflammatory role in 
peripheral tissues (Alitalo 2011). In fact, genetically modified mice with increased lymphatic 
network demonstrate enhanced capability to limit acute inflammatory reactions 
(Huggenberger et al. 2011). Thus, sufficient lymph drainage may indeed be crucial to resolving 
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acute inflammation in an attempt to prevent the development of chronic inflammatory 
conditions.  
 
Importantly, the imbalance between angiogenesis and lymphangiogenesis has been suggested 
to contribute to the sustained inflammation of atherosclerotic lesions (Nakano et al. 2005). 
Furthermore, lymphatic vessels in atherosclerotic plaques may be dysfunctional, which could 
add to this pathological imbalance (Alitalo 2011). Blood vessels also transport lipoproteins into 
tissue, whereas lymphatic vessels serve as an exit route for both lipids and inflammatory cells. 
Thus, blood vessels and lymphatic vessels counteract each other in several pathological 
processes during the pathogenesis of atherosclerosis (Alitalo 2011). All in all, as the amount of 
lymphatic vessels was relatively small as compared to blood vessels in the stenotic aortic valves 
(III), their imbalance may promote lipid accumulation and maintain chronic inflammation in 
AVS as well. 
 
The role of intraleaflet hemorrhage 
In atherosclerotic plaques, neovascularization may contribute to the accumulation of lipids and 
inflammatory cells into the lesions also via intraplaque hemorrhage, i.e. the rupture of the 
newly-formed, fragile blood vessels (Kolodgie et al. 2003). Notably, such enhanced 
accumulation of lipid and inflammatory cells may also occur via less prominent leakage through 
the immature vasculature as implied above. In our material (II), prominent intraleaflet 
hemorrhage, as evaluated by neovascular rupture and the presence of microscopic thrombotic 
masses, was extremely rare. However, the search for such changes was unsystematic, 
rendering it possible that the incidence of hemorrhagic changes was underestimated. A recent 
study does in fact describe abundant intraleaflet hemorrhage in the diseased valves, suggesting 
a parallel pathology with atherosclerosis in this respect (Akahori et al. 2011). Moreover, the 
presence of erythrocyte-positive extraluminal staining indicating intraleaflet hemorrhage 
associated with the rapid progression of clinical stenosis (Akahori et al. 2011). 
 
Angiogenesis and calcification 
Angiogenesis and osteogenesis are closely associated during bone development and 
remodeling. Interestingly, VEGF-A could be the factor connecting these parallel processes (Yang 
et al. 2012). VEGF-A-mediated capillary invasion is also required for normal growth plate 
function (Gerber et al. 1999), and VEGF-A may promote both endochondral ossification and 
intramembranous ossification by directly affecting osteoblasts and osteoclasts (Yang et al. 
2012). As discussed above (Results and discussion, 2.2.1), VEGF-D may also promote the 
differentiation of osteoblasts (Orlandini et al. 2006). Furthermore, pericytes may promote 
calcification by acting as progenitors for calcifying cells (Collett and Canfield 2005). 
Interestingly, this pathway has already been recognized as one of the factors behind 
pathological calcification of the arterial wall in atherosclerosis (Boström et al. 1993). Based on 
these findings, there is a plausible connection between angiogenesis and calcification in AVS. 
Other, weaker connections also exist. For instance, the formation of sprouting endothelial tip 
cells is regulated by NOTCH1 (Hellstrom et al. 2007), which has also been linked to aortic valve 
calcification (Garg et al. 2005). Without specific assessment, however, the relevance of these 
findings to AVS pathogenesis remains obscure. 
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3.1.3. Cause or consequence 
 
VEGF-A has been shown to induce the progression of atherosclerotic plaques in several animal 
models (Celletti et al. 2001). Moreover, inhibiting angiogenesis has resulted in reduced 
histological atherosclerosis in mice (Moulton et al. 2003). The role of angiogenesis in AVS, 
however, is mainly based on ex vivo histological evidence. Therefore the neovascularization of 
the stenotic aortic valves could also be a consequence rather than the cause of valvular 
thickening and inflammation. So far, only one in vivo study has assessed the significance of 
valvular angiogenesis in the development of AVS. Yoshioka and coworkers investigated the 
inhibitory effect of chondromodulin-I to angiogenesis in cardiac valves (Yoshioka et al. 2006). 
Remarkably, they observed increased lipid deposition and calcification in the aortic valves of 
mice with increased valvular angiogenesis due to chondromodulin-I downregulation. This 
finding indicates that valvular angiogenesis may, indeed, have a causal role in the development 
of AVS. Furthermore, the finding of Soini et al. indicating that even aortic valves with only mild 
stenotic changes contain neovessels suggests that valvular angiogenesis occurs in the early 
course of this disease (Soini et al. 2003). In any case, neovascularization may potentiate other 
pathological valvular processes by providing an entry route as well as nutrients and oxygen to 
the various cells sustaining valvular ECM remodeling and inflammation. Further investigations 
are required, however, to establish the exact role of neovascularization in this disease. As 
lymphatic vessels have remained unreported in animal models of AVS, assessing the balance 
between valvular angiogenesis and lymphangiogenesis in vivo remains an important long-term 
goal in the field of AVS research. 
 
 
3.2. Clinical applications 
 
3.2.1. Detecting valvular angiogenesis 
 
Multiple tools are already available for the detection of angiogenesis and inflammation in 
atherosclerotic plaques in research settings even in humans (Zagorchev and Mulligan-Kehoe 
2011). One group has also measured angiogenesis in the sclerotic aortic valves of cholesterol-
fed New Zealand White rabbits using integrin-targeted nanoparticles and 19-fluorine MRI/MRS 
(magnetic resonance imaging/spectroscopy) (Waters et al. 2008). They were able to 
demonstrate the development of detectable angiogenesis in this model, but possible 
correlations between the extent of angiogenic signals and histological findings were not 
included in the study design. Furthermore, the measurements were performed ex vivo, limiting 
the applications of this technique in humans. 
 
Disease progression rate was not assessed in the substudies of this thesis. In any case, the 
actual question would be how the in vivo measurements correlate with disease progression. 
Furthermore, in measuring the overall disease activity in a patient, all three leaflets should be 
accounted for in a three-dimensional manner instead of a cross-sectional assessment of one 
leaflet used in histological approaches. After addressing these initial questions, imaging disease 
activity in AVS could provide important clinical applications in the early detection of valvular 
disease, in recognizing patients with high risk of disease progression, and in targeting individual 
pharmacotherapies. 
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3.2.2. Pharmacotherapeutic possibilities 
 
A number of valvular processes leading to AVS, including those identified in this thesis, may be 
modulated even with existing pharmacotherapies (Cawley and Otto 2009, Parolari et al. 2009). 
The question remains if these therapies are still effective locally in the aortic valve, especially 
when the diagnosis is usually delayed to end-stage disease. Even if effective, restricting the 
effects of a drug therapy to the relatively small mass of aortic valve tissue is problematic. For 
instance, the systemic effects of a therapy aiming at the resolution of calcific masses in the 
valves could lead to a detrimental outcome in the bones. Finally, since the roles of many of the 
pathological processes remain unestablished in vivo, the ultimate consequences of successful 
therapy may be unpredictable even in valvular tissue. If these concerns could be addressed, a 
variety of possible candidates for pharmacological intervention stand in line to be tested in the 
treatment of AVS, even in the field of preventing valvular angiogenesis.  
 
Currently, the most promising drugs in AVS treatment are ACE-I/ARB medications. Two ongoing 
randomized clinical trials listed at clinicaltrials.gov assess the potential effects of ARB therapy 
on the progression of AVS, namely ROCK-AS (Helsinki, Finland; NCT00699452; Candesartan vs. 
placebo) and the ALFA Trial (Seoul, South Korea; NCT01589380; Fimasartan vs. placebo). 
Interestingly, there seems to be a regulative connection between LOX-1 and angiotensin II 
receptors; The activation of angiotensin 1 receptor induces the expression of LOX-1 and vice 
versa, the effects being counteracted by their respective receptor blockers (Wang et al. 2011). 
Thus, combining ARB medication with LOX-1-targeted therapy could further reduce the adverse 
effects of angiotensin II in the aortic valve. More importantly, ARB therapy could also act by 
reducing the adverse effects of oxLDL by means of downregulating LOX-1. Regarding the 
adverse effects of oxLDL, it may play a role in AVS pathogenesis even though the lipid-lowering 
statins seem to be ineffective in AVS (Rossebo et al. 2008). In fact, several investigations have 
indicated that the proangiogenic effect of oxLDL is more pronounced particularly at low 
concentrations (Dandapat et al. 2007, Khaidakov et al. 2012, Yu et al. 2011). Furthermore, the 
relative proportions of oxidatively and otherwise modified lipid particles are significantly 
increased in stenotic aortic valve leaflets as compared to healthy ones (Lehti et al. 2013). Thus, 
the pathological role of lipoproteins in AVS could be a question of quality rather than quantity, 
and the fact that statins produce a mass effect could at least partially explain the 
unsuccessfulness of lipid-lowering in the treatment of AVS. 
 
Both antiangiogenic and proangiogenic therapies targeting the VEGF family have been 
developed for the treatment of coronary atherosclerosis (Vuorio et al. 2012), since 
angiogenesis is mostly pathogenic in the arterial wall but desirable in the ischemic heart muscle 
after infarction. Other antiangiogenic therapies have been suggested as possible counteractors 
of valvular angiogenesis, including chemically modified tetracyclines and medications targeting 
the apelin pathway (Peltonen et al. 2009a, Salo et al. 2006). Some of these medications may, 
indeed, be useful in the future treatment of AVS in addition to other atheroinflammatory 
conditions. However, as stated above, the ultimate outcome of the inhibition of valvular 
angiogenesis should first be clearly established in adequate in vivo animal models before 
advancing to clinical settings with any of the antiangiogenic pharmacological agents.  
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3.3. Study limitations 
 
Immunohistochemical detection of valvular blood vessels with antibodies against CD31 and 
CD34 does not differentiate blood vessels from lymphatic vessels. Thus, lymphatic vessels may 
be included in valvular small and medium-sized microvessel counts. As the number of 
lymphatic vessels was relatively small (Figure 6A), and there is a positive correlation between 
lymphatic and blood vessels, a significant bias from this cross-detection is unlikely. 
 
VEGF-A has previously been detected only from cells co-expressing its receptors VEGFR-1 and -
2 (Soini et al. 2003). In the study in question, only protein, not mRNA, was analyzed at tissue 
level, leaving the unlikely possibility of ligand-receptor binding rather than actual local 
production. We found VEGFR-3 in valvular lymphatic vessels and surface endothelium, and 
processed forms of VEGF-C and -D may also bind to VEGFR-2 (Achen et al. 1998, Joukov et al. 
1997). Thus, ligand-receptor binding cannot be ruled out regarding our observations of 
immunohistochemical colocalization of VEGF-A (II), -C, and –D (III) with valvular myofibroblasts 
and endothelial cells. Nevertheless, VEGF-A (II) and VEGF-C (III) were also produced by cultured 
valvular myofibroblasts, and VEGF-A was detected in valvular mast cells lacking both VEGFR-2 
and -3 (II), indicating local valvular production of these VEGFs. 
 
The substudies in this thesis include data from tissue analyses and cell culture experiments 
from both AVS patients and control subjects. The lack of animal models limits the possibilities 
of drawing causal conclusions based on these data. The results may also be affected by the 
heterogeneity of the control material, which is a common problem in this field of research 
mainly due to availability issues.  In addition to patients undergoing cardiac transplantation due 
to cardiomyopathies and organ donors without any diagnosed heart disease, control valves 
were also obtained from patients undergoing valve replacement surgery due to aortic valve 
regurgitation (AVR). Even though only macroscopically and microscopically healthy valves were 
included in Studies I-IV, the valves from AVR patients potentially represent another valve 
pathology. The differences between the three control groups were analyzed in each substudy, 
however, and the results of AVR patients deviated from those of organ donor tissue only in the 
scavenger receptor qPCR analyses in Study IV. Consequently, AVR samples were excluded from 
Study IV, except for some of the cell culture experiments, where other control tissue was 
unavailable.
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VI SUMMARY AND CONCLUSIONS 
 
 
This thesis aimed at characterizing neoangiogenesis and lymphangiogenesis in aortic valve 
stenosis. We identified several factors involved in these processes, summarized in Figure 9. 
Based on our findings, the following conclusions can be presented. 
 
1) Cathepsins S, K, and V, and their inhibitor, cystatin C, are locally produced in aortic 
valves, and their activity is increased in AVS. In addition to promoting the stiffening of 
the valves by fractioning elastin fibers, these cathepsins may contribute to valvular 
angiogenesis by participating in the local ECM degradation, which enables endothelial 
cell migration and vascular sprouting. 
  
2) Stenotic aortic valves contain blood vessels and lymphatic vessels, and the balance of 
these vessels favors the accumulation of lipids and inflammatory cells into the valves 
rather than their clearance. Furthermore, mature arterioles, an advanced stage of 
angiogenesis, correlate positively with valvular calcification. 
 
3) Angiogenic and lymphangiogenic vascular endothelial growth factors and their 
receptors are locally expressed in the aortic valves. In addition, the expression of 
angiogenic and lymphangiogenic VEGF receptors is increased in stenotic aortic valves, 
suggesting that the VEGFs are involved in the pathogenesis of AVS. 
 
4) Activated mast cells in stenotic aortic valves secrete VEGF-A, and the VEGF-A secretion 
of mast cells is augmented by valvular myofibroblasts and vice versa. Mast cells are 
also capable of degrading the antiangiogenic endostatin and lymphangiogenic VEGF-C. 
Thus, valvular mast cells appear to possess angiogenic and antilymphangiogenic 
properties. 
 
5) The oxLDL-binding scavenger receptors SR-A1, CD36, and LOX-1 are expressed in the 
aortic valve. Furthermore, the expression of proinflammatory SR-A1 and 
proangiogenic LOX-1 are increased in AVS, whereas the potentially antiangiogenic 
CD36 is downregulated. Thus, changes in the expression of scavenger receptors in AVS 
may favor valvular inflammation and angiogenesis. Furthermore, oxLDL may even 
contribute to valvular angiogenesis indirectly by inducing the production of 
proinflammatory cytokines in aortic valve myofibroblasts. 
 
 
General conclusions and future prospects 
Valvular myofibroblasts, mast cells, and their interactions may contribute to angiogenesis in 
stenotic aortic valves. In AVS, the balance between blood vessels and lymphatic vessels is 
disturbed, which could facilitate the infiltration of lipids and inflammatory cells into the 
stenotic valve leaflets. Even if the complex mechanisms behind pathological valvular 
angiogenesis and lymphangiogenesis could be altered, pharmacological treatment targeting 
valvular angiogenesis is unlikely to reverse the pathological changes of end-stage stenotic 
valves. Rather than a pharmacotherapeutic target of AVS, angiogenesis could potentially serve 
as a target for valvular imaging. Conceivably, valvular angiogenesis could not only portray the 
SUMMARY AND CONCLUSIONS   │   65 
_____________________________________________________________________________ 
 
 
presence of valvular disease but also associate with disease progression. If disease activity 
could be detected at earlier stages, targeted follow-up and future pharmacological treatment 
could perhaps alter the currently inevitable consequences of this detrimental disease. 
 
 
 
 
Figure 9, modified from (III). Schematic illustration summarizing the main findings in this thesis 
and the proposed regulatory mechanisms of angiogenesis and lymphangiogenesis in AVS.  
  
(1) Cathepsins S and V are produced by valvular endothelial cells (I). These cathepsins may 
facilitate endothelial cell migration and vascular sprouting (I) (Shi et al. 2003).  
(2) Valvular myofibroblasts secrete VEGF-A (II), VEGF-C (III), and VEGF-D (III), and the 
production of VEGF-A by the myofibroblasts is increased by mast cell-derived components, 
hypoxic conditions, and cigarette smoke (II). Short-term osteogenic stress, in turn, decreases 
the secretion of VEGF-A (II) and VEGF-C (III) by the myofibroblasts.  
(3) Cigarette smoke can activate mast cells (Helske et al. 2006), and activated mast cells secrete 
VEGF-A (II). Furthermore, myofibroblast-derived factors promote VEGF-A secretion by the mast 
cells (II). Mast cells are also able to degrade antiangiogenic endostatin (II) and lymphangiogenic 
VEGF-C (III).  
(4) VEGF-A and VEGF-C are also produced by endothelial cells lining the valve as well as valvular 
neovessels, the former producing VEGF-D as well.  
(5) Valvular neovessels express VEGFR-2 (Soini et al. 2003) and lymphatic vessels express 
VEGFR-3. Both VEGFR-2 and -3 are upregulated in AVS (III). Valvular neovessels also express 
VEGF-A and -C, and the amount of pericyte-covered mature vessels increases with valvular 
calcification (II).  
(6) LOX-1 expression is increased in the endothelial cells of stenotic aortic valves (IV). OxLDL 
may thus increase VEGF-A secretion by the endothelial cells via LOX-1 (Dandapat et al. 2007). 
Oxidative modulation of LDL in the valves may also ensue from the actions of external risk 
factors such as cigarette smoke (Valkonen and Kuusi 1998). 
(7) Valvular neovessels may be harmful in AVS because they provide nutrients and oxygen to 
the proliferating myofibroblasts as well as form an entry route for inflammatory cells and lipids. 
Lymphatic vessels, in turn, could serve as an exit route. The imbalance between valvular 
angiogenesis and lymphangiogenesis may promote AVS progression by favoring lipid 
accumulation, inflammation, and thickening of the diseased valve leaflets. 
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